Targeting Ectopic Hsp90 in Breast Cancer by Barrott, Jared
  
 
 
Targeting Ectopic Hsp90 in Breast Cancer 
by 
Jared James Barrott 
Department of Pharmacology and Cancer Biology 
Duke University 
 
Date:_______________________ 
Approved: 
 
___________________________ 
Timothy A. J. Haystead, Supervisor 
 
___________________________ 
H. Kim Lyerly 
 
___________________________ 
Dennis Thiele 
 
___________________________ 
Bernard Mathey-Prevot 
 
 
 
 
Dissertation submitted in partial fulfillment of 
the requirements for the degree of Doctor 
of Philosophy in the Department of 
Pharmacology and Cancer Biology in the Graduate School 
of Duke University 
 
2014 
 
 
  
 
ABSTRACT 
Targeting Ectopic Hsp90 in Breast Cancer 
by 
Jared James Barrott 
Department of Pharmacology and Cancer Biology 
Duke University 
 
Date:_______________________ 
Approved: 
 
___________________________ 
Timothy A. J. Haystead, Supervisor 
 
___________________________ 
H. Kim Lyerly 
 
___________________________ 
Dennis Thiele 
 
___________________________ 
Bernard Mathey-Prevot 
 
 
  
 
An abstract of a dissertation submitted in partial 
fulfillment of the requirements for the degree 
of Doctor of Philosophy in the Department of 
Pharmacology and Cancer Biology in the Graduate School of 
Duke University 
 
2014 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright by 
Jared James Barrott 
2014 
 
  
iv 
Abstract 
On the surface heat shock protein 90 (Hsp90) is an unlikely drug target for the 
treatment of any disease, let alone cancer. Hsp90 is highly conserved and ubiquitously 
expressed in all cells. There are four major isoforms encoded by distinct genes and 
together they may constitute 1–3% of the cellular protein. Genetic deletion results in 
nonviable phenotypes in some organisms, and there are no recognized polymorphisms 
suggesting an association or causal relationship with any human disease. With respect to 
cancer, the proteins absence from some recent high profile articles underlines the 
perception that it is an unlikely bona fide target to treat this disease. Yet, to date, there 
are 17 distinct Hsp90 inhibitors in clinical trials for multiple indications in cancer. The 
protein has been championed for over 20 years by the National Cancer Institute as a 
cancer target since the discovery of the antitumor activity of geldanamycin. Rather than 
focus on the intracellular inhibition of Hsp90, we have shifted our aim to the differences 
of Hsp90 between cancer and normal tissue, namely its extracellular expression. 
My graduate thesis work has focused on the characterization of a series of novel 
small molecule imaging agents (fluor-tethered Hsp90 inhibitors) that enable the specific 
detection of ectopically expressed Hsp90 on tumor cells. We believe that these molecules 
will have a large impact in the near future on the diagnosis and treatment of metastatic 
breast cancer as well as other cancers. This hypothesis is based on recent findings in the 
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clinical literature that have linked upregulation of Hsp90 with poor outcomes in 
multiple subtypes of breast cancer. Additionally, several papers have also reported an 
association of the expression of extracellular Hsp90 and metastatic progression in 
several human cancers. Hsp90 is currently considered by some as a cutting edge cancer 
drug target. The Haystead lab synthesized a series of tethered Hsp90 inhibitors that 
were modified with fluorophores and other imaging moieties in such a way as to 
preserve the binding to Hsp90 and enable detection through non-invasive imaging 
techniques. In a series of cell-based, live animal and biochemical studies we 
demonstrated that these molecules are highly selective for Hsp90 and can be used to 
specifically recognize intact tumor cells expressing ectopic Hsp90. Furthermore, we also 
observed that once bound to ectopic Hsp90, our tethered-inhibitors are actively 
internalized and this process can be blocked with Hsp90 antibodies. These findings have 
two implications; first, Hsp90 is undergoing active cycling at the plasma membrane; 
second, the finding that once bound to surface Hsp90 our fluor-tethered inhibitors can 
be internalized despite their polar nature. These results suggest a new therapeutic 
strategy that will enable specific delivery of tumor killing agents (e.g. 131I or metabolic 
poisons) to metastatic cells. This is unique because the use of small molecule inhibitors 
and not antibody- or nanoparticle-based payload delivery strategies offers advantages in 
formulation, cost and reproducibility. 
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 In addition to payload delivery possibilities, we also show the utility of the 
tethered-inhibitors diagnostically by demonstrating their use in the detection of tumors 
in mouse models of human breast cancer. As a result of our animal studies, we believe 
our molecules in their present form could be used to address a currently unmet need in 
the early diagnosis of aggressive breast cancer and discriminating this from more 
indolent forms.  
Furthermore, the tethered Hsp90 inhibitors have been used to make ligand 
affinity chromatography resins that have facilitated the discovery of other unique Hsp90 
expressions and functions associated with cancer. We have found a pool of Hsp90 that is 
misfolded as determined by affinity chromatography depletion and a leftward thermal 
stability shift in the population of Hsp90 that flows through the ligand affinity resins. 
Differential trypsin digest patterns detected by mass spectrometry reveal also that the 
native protein has sites that are more accessible to trypsinization. This could have 
further implications in treating and detecting differences between cancerous tissues and 
normal tissues by designing an antibody that recognizes the exposed portions of the 
misfolded Hsp90. Together this body of work illustrates that not only is Hsp90 different 
in total expression levels in cancers, but is ectopically expressed and misfolded so as to 
provide other opportunities for therapeutic intervention that improve the safety for 
more clinical applications. 
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1. Introduction  
Undoubtedly, any protein or gene of interest that has relevance to cancer will 
receive superfluous recommendations to pursue it pharmacologically. Heat shock 
protein 90 (Hsp90) is no exception. With each new interaction and publication about 
Hsp90 there is augmenting enthusiasm to pursue clinical applications. The fact of the 
matter is that Hsp90 inhibitors are being pursued and advancing through clinical trials 
and their applications toward multiple cancers are expanding. Despite these successes, a 
few recent high-profile articles on the mechanisms of cancer have overlooked this 
already established therapeutic target, and it does not appear to be an anomaly with the 
authors of these cancer reviews1,2. Many cancer pharmacologists are often blindsided by 
the clinical trial data or even the notion that one could target an abundant chaperone 
protein, such as Hsp90 that has no known disease-linked polymorphisms3,4. On the 
surface this seems reasonable, how could one pharmacologically target a protein that is 
essential for normal cell viability and has a documented interactome that involves over 
400 putative clients and over a dozen cellular pathways and processes?  
Because it was hard to envision any clinical success at first, the application of 
Hsp90 inhibitors was relinquished to purely academic exercises as pharmaceutical 
companies considered it inconsequential. However, despite the high abundance and 
pleiotropic effects of Hsp90 protein-protein interactions, Hsp90 inhibitors have 
advanced into clinical trials. Counterintuitively, the aspects that at first made Hsp90 
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inhibitors seem inappropriate are now demonstrating advantages over single target 
therapies, and the potential of combination therapies that include Hsp90 inhibitors 
should effectively prevent or prolong the development of cancer drug resistance that is 
commonly seen with tyrosine kinase inhibitors and other target-based therapies5-7. 
To underline the improved successes of Hsp90 inhibitors, we highlight results 
published for ganetespib, an Hsp90 inhibitor developed by Synta Pharmaceuticals 
(Lexington, MA, USA). In in vitro tumor cytotoxicity studies, it was shown that a five 
minute exposure to ganetespib at 1 µM (a readily achievable plasma level in vivo) was 
sufficient to induce cell death within 72 hours. This suggests that a brief exposure to 
Hsp90 inhibitors results in a permanent and lasting effect on the cell. These observations 
extend to animal studies. A single weekly dose of 100-150 mg/kg for 3 weeks resulted in 
50-90% tumor reduction in solid and hematological xenograft models8. Most 
importantly, in recent clinical studies it was also shown that once weekly ganetespib 
treatment in patients with non-small cell lung carcinoma (NSCLC) resulted in a 50% 
overall response rate9,10. Development of ganetespib in many ways is therefore a good 
example of how second generation synthetic Hsp90 inhibitors are surpassing their first 
generation geldanamycin-based counterparts. Ganetespib not only shows increased 
efficacy and improved formulation over the geldanamycins, but also significantly 
reduced cardiovascular and hepatotoxicity side effects8. In our view such consistent 
advances are a testament to the validity of Hsp90 as a druggable target. While safety for 
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off target effects is being improved and desired tumor effects continue to progress, the 
mechanisms for Hsp90 targeting in tumors over Hsp90 found in normal tissue is less 
understood. 
1.1 Hsp90, the basics 
To frame this thesis, I offer a brief overview of the basics of Hsp90 and its known 
biology and then address the distinguishing characteristics of Hsp90 between cancer 
cells and normal cells. Hsp90 plays an essential role in maintaining cellular protein 
homeostasis by acting as a molecular chaperone to aid in folding as well as in 
intracellular trafficking of its protein clients11,12. It is expressed as a 90 kDa protein 
(Hsp90α 732 aa; Hsp90β 724 aa) in the cytosol and the nucleus and contains an N-
terminal ATP binding domain that is essential for most of its cellular functions13. ATP 
hydrolysis is thought to drive various conformational changes within Hsp90 and this 
process is highly regulated by interactions with co-chaperones and possibly a variety of 
posttranslational modifications (Table 1)12,14. Through these mechanisms the apparent 
ubiquitous cellular chaperone functions of Hsp90 are thought to be acutely regulated.  
Much effort has been seen in the past two decades to characterize the specific 
protein interactions with other proteins termed co-chaperones. Co-chaperones assist 
Hsp90 throughout its conformational cycling that is required for its normal function, act 
as substrate recognition proteins and even provide additional enzymatic activity. The 
predominant class of co-chaperones is the tetratricopeptide repeat domain (TPR)-
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containing proteins, which bind the MEEVD motif found in the C-terminus of Hsp9015-18. 
Among the co-chaperones with a TPR domain are CHIP, Hop, Cyp40, FKPBs and PP5. 
While most co-chaperones facilitate the recruitment of other substrate proteins, some of 
these co-chaperones add enzymatic functionality to the chaperone complex as is the case 
for the isomerases, phosphatases, and ligases19-21. Other co-chaperones that interact with 
Hsp90 via alternative domains are Aha1, which enhances the function of Hsp90 by 
stimulating its ATPase activity22,23. The co-chaperone that is most implicated in 
facilitating tumorigenesis is Cdc37 because it associates with mutant kinases that drive 
cancer progression24. Recently it was shown that the Hsp90-Cdc37 complex binds two-
thirds of the kinome to varying degrees, while at the same time demonstrating 
negligible interactions with ligases and transcription factors25. Another co-chaperone 
that is responsible for the complexing of nuclear hormone receptors and Hsp90 is p23. 
However, its interactions are not as limited as Cdc37, as p23 has been found in a broad 
range of Hsp90-client complexes26-29. Unlike the activating co-chaperone, Aha1, the co-
chaperones Cdc37, p23, and Hop inhibit ATPase activity. These co-chaperones therefore 
add another layer of regulation of this multifaceted master chaperone, underling the 
complexity of the Hsp90 chaperone cycle and its folding functions. Hsp90 is also 
regulated transcriptionally, primarily through direct interactions with the transcription 
factor HSF30. Despite its high level of expression in normal cells, cellular stresses such as 
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heat shock (37°C to 42°C) have been reported to induce Hsp90 protein levels by as much 
as two fold31. 
Two other immediate family members, Glucose Regulated Protein 94 (Grp94) 
and TNF Receptor Associated Protein 1 (TRAP1), share sequence similarity in the ATP 
binding domain and are also thought to act as cellular chaperones to promote protein 
stability and folding either in the mitochondria (TRAP1) or endoplasmic reticulum 
(Grp94), albeit they do not exemplify the same complexity and vast interactions that 
Hsp90 exhibits32. Like Hsp90, Grp94 and TRAP1 contain an N- terminal ATP binding 
domain and ATPase activity that is also necessary for cellular function33-36. Unlike 
Hsp90, the list of client proteins interacting with either Grp94 or TRAP1 is much more 
limited and less well defined. Several groups have proposed that Grp94 and TRAP1 are 
additional potential targets that can be exploited as cancer chemotherapies, although 
selective inhibitors of these proteins have yet to show clinical promise.   
A surprising and common finding with most Hsp90 inhibitors is their selectivity 
for certain tumor cells and not other cells. With few exceptions in vivo, most cancer cells 
are more sensitive to Hsp90 inhibition than non-transformed cells and non-toxic doses 
demonstrate anticancer activity. In animals and humans, Hsp90 inhibitors consistently 
accumulate in tumors whereas they are rapidly cleared from plasma and do not appear 
to enter most tissues37-43. One notable exception may be the retina. Although 
idiosyncratic in nature, a reversible ocular toxicity has been observed in some patients 
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with some but not all Hsp90 inhibitors44. Generally this occurs at higher dosing or after 
prolonged exposure and manifests as a loss of night vision. Drug withdrawal or dose 
reduction usually reverses the symptoms. However, the idiosyncratic nature of the 
phenomenon suggests that the mechanisms of drug accumulation in the retina may be 
different from tumor cells and perhaps related to some underlying eye pathology in 
patients that are most susceptible. Alternatively, the structural variations of different 
Hsp90 inhibitors permit varying degrees of cellular uptake, with the retina being more 
susceptible than most other tissues. The fact that certain tumor cells preferentially 
absorb Hsp90 inhibitors strongly suggests that specific mechanisms exist within these 
cells that contribute to the druggability of Hsp90.  One early hypothesis suggested that 
in tumor cells Hsp90 preferentially exists in chaperone complexes and these 
multiprotein complexes were reported to exhibit a higher affinity for Hsp90 inhibitors as 
well as higher ATPase activity45. Experiments with affinity resins based on immobilized 
Hsp90 inhibitors suggest a large imbalance of Hsp90 to its co-chaperones in both normal 
and transformed cells46,47. A simple mechanism that could explain the drug 
accumulation may be that tumor cells simply express more Hsp90 than normal cells. 
Certainly, transformation has been shown to induce expression of Hsp90 at the protein 
level and this can also be measured in tumors isolated from patients. However, even in 
the most extreme case the fold inductions are 2-3 fold at best at the protein level. As 
discussed, in normal cells Hsp90 is thought to constitute 1-2% of the cellular protein and 
 7 
many believe that high expression of Hsp90 is evolutionarily conserved. Indeed, normal 
Hsp90 expression levels beg the question as to why tumor cells would need to induce 
more expression of the protein. We align our theory with others that the abundance of 
Hsp90 is evolutionarily conserved for a purpose and not wastefully guarded to bewilder 
scientists. If we can come to an understanding of the mechanisms that accentuate the 
tumor differences, Hsp90 inhibitors could be universally employed to fight the 
constantly evolving battle on cancer.  
In this introduction I will discuss the mechanisms that differentiate tumor Hsp90 
from the Hsp90 that is abundantly expressed in normal tissues, thereby making it a 
druggable cancer target. The three mechanisms, not mutually exclusive, that are the 
most important in distinguishing Hsp90 in cancer cells from Hsp90 in non-transformed 
cells are (1) the induction of Hsp90 mRNA and protein (2) the activation of the protein 
through either client association or post-translational modifications (3) the localization to 
ectopic cellular compartments (Figure 1). As we understand more clearly the 
mechanistic differences in tumor biology and normal cellular biology regarding Hsp90, 
the remaining hurdles for Hsp90 inhibitors to enter routine clinical practice will be 
overcome. For reviews on the current status of clinical applications of Hsp90 inhibitors 
see the following37,48-53. 
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Figure 1: Differential patterns of expression of Hsp90 in cancer 
 
1.2 Induction 
First, we look at the differential expression of Hsp90. Few will argue that Hsp90 
is overexpressed in tumors 2-3 fold higher than corresponding non-tumorigenic tissue, 
but even under basal conditions Hsp90 is abundant comprising 1-3% of the total cellular 
protein46,51,54,55. Hsp90 is upregulated in response to cellular stress imposed by heat, 
hypoxia and nutrient deprivation, which are commonly associated with the tumor 
microenvironment. Thus it has been proposed that Hsp90 upregulation in tumors is 
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essential to surviving the harsh microenvironment by allowing unstable mutations to 
persist that drive tumor malignancy56.  
In one of the strongest cases for clinical applications, hormone and protein kinase 
dependent breast cancer, Hsp90 expression levels have been well characterized and 
correlated to patient outcome of survival. First, Hsp90 expression in the breast has been 
recently evaluated immunohistochemically (IHC) for various types of tissue: normal, 
pre-malignant, and malignant. Hsp90 was shown to be expressed at higher levels in 
cancer tissues compared to non-cancer tissues57. Also Pick and colleagues performed 
IHC analysis of breast cancer cell lines and 655 primary breast cancers, including 331 ER+ 
and 324 ER- tumors, and found detectable Hsp90 expression in all of the breast cancer 
cell lines and in 90% of primary breast cancers. In addition, they reported that high 
expression of Hsp90 is associated with poor prognosis58. Because of the recognition of 
specific molecular subtypes of breast cancer, biostatisticians at Duke evaluated Hsp90 
gene expression from profiles of over 4,000 breast cancer patients from 23 publically 
available gene expression databases, annotated with overall survival data from over 
1,000 patients.  They found a normal distribution of Hsp90 expression, and confirmed 
that high expression of Hsp90 was associated with a poor overall survival59. It has also 
been shown in melanomas, leukemia, and human colonic carcinoma, that Hsp90 is 
elevated in the transformed and even more malignant tumors60-62. Elevated levels are 
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also being detected in the serum of patients with non-small cell lung cancer and prostate 
cancer63,64.  
Based on these studies it is believed that high expression of Hsp90 represents an 
important oncogenic signaling node for malignant behavior in cancer and detecting 
upregulation or activation of Hsp90 in cancer cells could be an early indicator of 
malignant behavior. However, increased Hsp90 expression is not sufficient to explain 
the mechanisms that drive tumorigenicity. One discrepancy is that even though Hsp90 is 
elevated in breast tumors compared to normal breast tissue, there are other normal 
tissues such as the bladder, spleen, and brain that express higher Hsp90 in the ratio of 
total Hsp90:total protein55,65. This leads to the argument that there is something unique 
about the protein in cancer cells that distinguishes it from Hsp90 found in normal tissue. 
With hundreds of putative client proteins and over 30 sites where post-translational 
modifications can occur, one can easily envision a scenario where tumor Hsp90 proteins 
are poised to behave differently than normal Hsp90. 
1.3 Activation 
Hsp90 is implicated in cancer cell survival and growth through its transient 
interactions with client proteins. Over 400 clients have been thought to be identified thus 
far and many of these are involved in mediating signal transduction pathways that 
govern cellular growth, apoptotic evasion, differentiation, and metastasis25,66-68. For a 
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current and comprehensive list of reported Hsp90 protein interactions visit the Picard 
lab’s website at http://www.picard.ch/Hsp90Int/index.php.  
Due to the fact that Hsp90 inhibitors preferentially target tumors, one may infer 
that these drugs target a subset pool of Hsp90, and this subset exhibits a high affinity 
conformation of Hsp90 for the inhibitors. One possibility is that Hsp90 exists in a 
multichaperone complex with transformation-specific oncoproteins, such as classical 
mutant kinases, Her2 and Bcr-Abl. These proteins may represent a small fraction of the 
client proteins regulating the transformed phenotype. The latent Hsp90 complexes 
regulating normal misfolding processes and comprising at any time the majority of total 
cellular Hsp90 may not be effectively inhibited by these drugs at the relatively nontoxic 
doses used. Such an interpretation leads to the hypothesis that, under normal 
conditions, Hsp90 interacts with client proteins in a dynamic manner regulated by low-
affinity binding and release of ATP and ADP. Upon mutation or deregulation, which is 
characteristic of the cancer phenotype, many of these client proteins may display 
unusually stable association with Hsp90, representing the active and druggable state. 
A 2003 Nature paper by Kamal et al claimed that Hsp90 in tumors exist entirely 
in multi-chaperone complexes and that when Hsp90 is in these specific complexes it has 
higher ATPase activity and a 100-fold higher affinity for the inhibitor 17-AAG45. 
However, one incorrect assumption was that all Hsp90 has an equal opportunity of 
binding ATP or its mimetics that are immobilized to a bead. We and others have shown 
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that only a fraction (20-30%) of Hsp90 binds to ATP or its ligands. Radiolabeled PU-H71 
also only labeled 30% of the Hsp90 in MDA-MB-468 cells and only half that in CML 
cells46. As far as co-chaperone involvement, Kamal et al demonstrated that when Hsp90 
was reconstituted in vitro with Hsp70, Hsp40, Hop, and p23, the highest ATPase activity 
was observed. Moulick et al also showed that Hsp90 recognized by immobilized ligand 
precipitated the co-chaperones Hsp70, Hsp40, Hop, and Hip and that these co-
chaperones were not found in the fraction of the antibody-isolated Hsp90, but they were 
found in the flow through45,46. It is thus hypothesized that the population of Hsp90 that 
binds to the ligand also exists in complex with several co-chaperones, but the “inactive” 
pool does not exist with co-chaperones. In their in vivo analysis they found that mouse 
tumors when compared to corresponding normal tissue do not differ that much in total 
Hsp90 levels as determined by western blotting. However, their ATPase activity was 
higher and their affinity for Hsp90 inhibitors was more45, thus supporting that 
transformation and malignancy cannot be explained solely by the elevated expression of 
Hsp90. On the other hand, efforts to replicate this work have failed to show the 
exclusive complex of Hsp90 found in cancer. In regard to the complex having a higher 
affinity for Hsp90 inhibitors, it is believed to be an artifact of non-specific binding to the 
affinity resin. Our lab has shown that non-specific binding to an Hsp90 affinity resin 
decreases upon extending the ligand away from the immobilized bead. Hsp90 was 
cleanly and competitively eluted from the affinity resin47, suggesting an alternative 
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hypothesis that when Hsp90 is in complex with an inhibitor that targets the ATP-
binding domain, co-chaperones that should be in stoichiometric abundance are 
displaced and not recovered.  
The studies to elucidate the client-chaperone interactions for Hsp90 are 
incomplete and provide little rationale for these interactions. For example, Hsp90 does 
not recognize an amino acid sequence that is common among the vast array of putative 
client proteins, nor do proteins within the same family that are structurally similar 
interact with Hsp90 in a comparable manner, such as is the case with EGFR and Her2. In 
the many criticisms that have been offered for the various approaches of identifying the 
Hsp90-client interaction, whether it is by immunoprecipitation, yeast two-hybrid assays, 
or mass spectrometry analysis, a recent study attempted to circumvent previous 
obstacles by expressing tagged potential client proteins (i.e. kinases, ligases, and 
transcription factors) with essential co-chaperones in order to study the interactions in a 
quantifiable manner. While no specific recognition sequence or structure was 
determined, the researchers concluded that a co-chaperone, Cdc37 in this case, provided 
a recognition of an as yet undefined fold and the thermal and conformational stability 
determined the extent of the interaction of Hsp90 with many of its kinase clients25. 
Cynically, one could also conclude from this study that any denatured protein is more 
likely to interact with Hsp90 than properly folded ones. Certainly the observation that 
inclusion of protein kinase inhibitors generally reduced binding to Hsp90 supports such 
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a notion. Expressed protein kinases are generally stabilized in the presence of ATP 
competitive inhibitors as reflected by an increase in thermal stability. In our experience, 
studies that use assays relying on affinity pull downs to study protein-protein 
interactions are fraught with artifacts and designing the appropriate controls to prove 
that interactions are real is not easy. Our own experience in the development of affinity 
resins targeting Hsp90 revealed the importance of carrying out appropriate controls in 
discriminating proteins that bind directly to Hsp90 versus those that are non-specific. 
We have shown that changing the linker that is used to immobilize an Hsp90 inhibitor 
can dramatically affect the patterns of proteins recovered from a cell extract (see page 
81). One could conclude for example from the resin shown in the decane linker lane that 
this resin recovers a large amount of Hsp90 clients in addition to Hsp90. However, by 
blocking binding of Hsp90 itself to the affinity media by including a free Hsp90 inhibitor 
in the cell extract prior to mixing with the affinity resin shows that although recovery of 
Hsp90 is blocked, none of the other proteins are affected showing these are artifacts and 
have nothing to do with Hsp9047. Ultimately this has led us to develop a media that 
clearly recovers only Hsp90 and very little else including co-chaperones. We are 
somewhat perplexed by the absence of the Hsp90 interactome with this affinity resin, 
despite the observation that it clearly recovers Hsp90 in a competitive manner. Our own 
conclusions from these studies is that the Hsp90 interactome should be revisited using 
more rigorous controls such as including Hsp90 inhibitors in control extracts to 
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eliminate non-specific binding to the resin surface. We feel that such studies are likely to 
shorten the stable interactome considerably.  
Having suggested that affinity based approaches might lead to misidentification 
of clients; other approaches examining client fate in the presence of an Hsp90 inhibitor 
may be more informative. Many studies that try to establish Hsp90 client associations 
evaluate the fate of the putative client after Hsp90 inhibition. Most often cited is the 
degradation of a given client, while those proteins that persist are thought not to be 
chaperoned by Hsp90. The best example of this phenomenon is the degradation of Her2 
in breast cancer cell lines treated with Hsp90 inhibitors. We can acknowledge that by 
Western blot we can confirm recovery of Her2 with Hsp90 on our most selective Hsp90 
resin47. Importantly, this recovery is blocked by the inclusion of an Hsp90 inhibitor in the 
cell extracts prior to mixing with the affinity media. We do note however, that the ratio 
of active drug bound Hsp90 recovered relative to Her2 is at least two orders of 
magnitude higher (Hsp90:HER2). As suggested in studies by Lindquist and colleagues, 
Hsp90 interacts with its clients transiently or with low affinity, at least in the drug 
bound state25.  Client degradation approaches also have their caveats, for example it is 
common knowledge that the fate of unfolded proteins varies as some are degraded with 
differing kinetics and others form more stable aggregates when improperly folded. 
Thus, the lack of sensitivity to Hsp90 inhibition cannot fully explain the interactions or 
discredit client interactions. Additional caveats in establishing clients is that only a 
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fraction of Hsp90 is considered active due to its ability to bind inhibitors in its ATP-
binding pocket leaving the remaining Hsp90 pool to continue its chaperoning functions. 
With many uncertainties in the reported clients and no clear way to establish a 
transient interaction for a protein that is otherwise stable without the chaperoning 
functions of Hsp90, the nature of defining a general activated state of Hsp90 in cancer 
will continue to be difficult to attain. However, much progress is being made in the 
differences in cancer Hsp90 compared to normal tissue Hsp90 in regards to its post-
translational modifications. These modifications are now demonstrating their effects in 
ATPase activity, as well as localization, which in turn are affecting the association Hsp90 
has with other proteins. For a comprehensive list of reported modifications see Table 1. 
Hsp90 modifications that influence localization are highlighting some of the stronger 
differences that are being observed in cancer cells over normal tissue. 
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Table 1: Reported posttranslational modifications for Hsp90 and their effects 
on protein function 
Modification Hsp90α  
Residue 
Enzyme Result 
4-HNE, 4-ONE C572  Decreased client association69  
Acetylation K294 HDAC6 Decreased client association70 
Acetylation K69, K100, 
K292, K327, 
K546, K558 
p300, HDAC6 Increased inhibitor binding, 
increased extracellular 
expression71-75 
Dephosphorylation  Ppt1/PP5 Decreased chaperone function76 
Phosphorylation Y309 SRC VEGFR2-induced 
angiogenesis77 
Phosphorylation S231, S263 CK2 Increased apoptosome 
formation, decreased client 
association78,79 
Phosphorylation Y38 Swe1/Wee1 Increased client association, 
decreased inhibitor binding80,81 
Phosphorylation T36 CK2 Decreased ATPase activity, 
increased  inhibitor binding82,83 
Phosphorylation Y197 Yes Decreased co-chaperone 
association84  
Phosphorylation Y309 Yes Increased co-chaperone 
association84  
Phosphorylation T5, T7  DNA-PK Increased extracellular 
expression85,86 
Phosphorylation T  P2X7 receptor repressor87 
Phosphorylation S263 B-Raf unknown88 
Phosphorylation S460 PKA unknown89 
Phosphorylation T90 PKA Increased extracellular 
expression, decreased client 
association90,91 
S-nitrosylation C597 eNOS Decreased chaperone function, 
decreased ATPase activity92,93 
Ubiquitination   Decreased client association94  
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1.4 Localization 
The emphasis of distinguishing tumorigenic Hsp90 from normal Hsp90 is being 
placed in the field of client association. Post-translational modifications are thought to 
influence the association of Hsp90 with its clients, and in the past decade, the 
community of Hsp90 has begun to reveal how post-translational modifications affect the 
localization of Hsp90. More importantly, they have shown that ectopic localization can 
lead to the progression of a more malignant phenotype of most cancers.  
No longer is Hsp90 being considered to reside exclusively in the intracellular 
milieu, but can be found on the surface membrane of a variety of cancer cells, as well as 
being secreted into the extracellular space60,95. The fact that cell surface Hsp90 is higher 
in some cancer cells than normal cells makes it an even more attractive target to 
destabilize metastatic pathways that are dependent on surface Hsp90 for invasion and 
migration. Since the initial screen in 2004 that implicated Hsp90 in cell invasion and 
migration, multiple researchers have shown that blocking or neutralizing secreted 
Hsp90 has had an inhibitory effect on these metastatic behaviors96,97. While we still do 
not understand the mechanisms responsible for Hsp90 extracellular expression, certain 
environmental stresses and growth factors have been shown to stimulate its secretory 
pathways98,99. The secretion of Hsp90 also appears to be influenced by the post-
translational modifications, such as acetylation and phosphorylation72,85. 
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The presence of Hsp90 outside the cell was first discovered in 1986 when a 
mouse tumor-specific antigen was found to be a heat shock protein, now recognized as 
Hsp90100. In 2004, it was published that Hsp90 was discovered in a functional screen 
looking at cell surface proteins that are necessary for cell invasion, but due to the cellular 
abundance of Hsp90 it was first viewed as an artifact. However, the screen was 
validated and Hsp90 was determined to be biologically important in the mechanisms of 
cell invasion as it was established that it interacts with and activates matrix 
metalloproteinase-2 (MMP2)96.  Also in 2004, it was observed that in flow analysis of 
malignant melanoma that isolated tumor cells exhibited surface expressed Hsp9060. In 
the same year it was reported that surface Hsp90 plays a role in the migration of 
developmental neurons. Both Hsp90α and β are expressed on the surface of rat primary 
neural cells and antibodies against Hsp90 inhibited cell motility and lamellapodia 
formation. In this study crude measurements were made to determine the relative 
expression of surface Hsp90.  Ratios of surface to total levels of Hsp90 were obtained 
and surface Hsp90 represented < 10% of total cellular Hsp90101. Others have shown that 
tumor cell lines excrete Hsp90 into the conditioned medium and the lack of other 
classical intracellular proteins such as actin and tubulin argues that the Hsp90 does not 
come from lysed cells. In one study of dying cells, acrylamide-induced necrosis leads to 
extracellular release of Hsp90 and increased HSF1 activity.  Extracellular Hsp90 could be 
considered a danger signal to the immune system that something is detrimental to the 
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cells102. However, it is unknown what external cues trigger the excretion of Hsp90 in 
necrotic cells.  
Because intracellular Hsp90 plays a key role in proteomic homeostasis, it begs 
the question, are its chaperoning functions required outside the cell or does it play a 
different role altogether? It is known that intracellular misfolded proteins have three 
possible fates: chaperoning, proteolysis or aggregation. It appears that extracellular 
proteins require chaperoning as well. Compared with intracellular fluid, extracellular 
fluids have a lower protein concentration, 6% in plasma and 2% in interstitial fluid, as 
opposed to 30% in cytosol103. It is thought that extracellular Hsp90α functions with the 
co-chaperones, Hsp70, Hsp40, Hip, Hop, and p23, to assist in the cleavable activation of 
MMP-2 and can do it independently of ATP, an important feature for performing its 
function in an environment where ATP is drastically reduced104.   
Normal cells secrete Hsp90 but only when they are subjected to a compromised 
environment, such as heat, ROS, gamma-irradiation and injury released growth factors, 
whereas tumor cells constitutively secrete Hsp9098. Early researchers proposed that 
Hsp90 is secreted by a non-canonical secretory pathway because Hsp90 lacks the 
conventional signal peptides in secretory proteins as well as post-translational 
modifications such as N-glycosylation. Also Hsp90 is not localized to the ER and Golgi 
apparatus and Hsp90 secretion is resistant to BrefeldinA treatment, a classical inhibitor 
of ER/Golgi dependent secretion105. Indeed it has been demonstrated that Hsp90 is 
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excreted through the exosome pathway98,106. McCready et al showed that exosomes 
harvested from MDA-MB-231 cells were applied to other invasive cell lines in a wound 
healing assay and both exogenous exosomes and recombinant Hsp90 stimulated faster 
migration into the scratched area. Conditioned medium was immunoprecipitated for 
Hsp90α and 10 client proteins were identified by mass spectrometry. The complex of 
interest was Hsp90:AnnexinII:tPA:plasminogen, which results in the activation of 
plasmin, a key protein in tumor invasion and cancer metastasis106. Why however, is 
some Hsp90 targeted for exosomal secretion while the majority remains in the cell? 
Additionally, secretion of Hsp90 does not appear to be isoform specific as first 
speculated, with the recent finding of Stellas et al. who showed breast cancer cells also 
secrete the β isoform96,98,99,107. 
Some speculated whether or not the numerous possibilities for protein 
modification distinguish Hsp90 for secretion. Knockdown of HDAC6 results in 
increased acetylation which in turn decreases ATP binding and chaperone activity in 
Hsp90. Seven lysine residues on Hsp90α revealed hyperacytelation by mass 
spectrometry (Table 1), and acetylation increased 17-AAG binding to Hsp90, whereas 
K294 acetylation in the middle domain affects co-chaperone binding. Hyperacetylated 
Hsp90 was found extracellularly and promoted in vitro breast cancer cell invasion. 
Additionally, an antiactyl lysine-69 Hsp90α antibody markedly inhibited the cell’s 
invasiveness. P300 is the putative histone acetyl transferase responsible for acetylating 
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Hsp90α. The Hsp90α K292Q mutant showed increased binding to ATP whereas the 
other K to Q mutations at the other sites showed decreased binding. However, all the 
acetylated mimetics demonstrated increased binding to biotinylated-geldanamycin72. 
While acetylation appears to play a role, others suggest that it is the phosphorylation of 
T5 and T7 of Hsp90α and others suggest that it is a C-terminal truncation85,90. It was 
shown that the secreted Hsp90 is a C-terminal truncated form and its secretion was 
regulated by the C-terminal EEVD motif via interacting with proteins containing TPR 
domains. It was also demonstrated that the secretion of Hsp90 was determined by the 
phosphorylation status at residue Thr-90, regulated by protein kinase A and protein 
phosphatase 5. It was further demonstrated that the secretion of Hsp90 is a prerequisite 
for its pro-invasive function and blocking the secreted Hsp90 resulted in significant 
inhibition of tumor metastasis. Meanwhile, the level of plasma Hsp90 was positively 
correlated with tumor malignancy in clinical cancer patients90. 
While the precise mechanisms by which Hsp90 is targeted for exosomal secretion 
remain unclear, it is well established that extracellular Hsp90 plays pivotal roles in 
driving a non-motile tumor cell to become motile and invasive. Hsp90 facilitates each 
step in the three step model for tumor invasion: degradation of the extracellular matrix, 
adhesion, and migration of the cancer cells108. These events most likely are coordinated 
with intracellular chaperoning functions that drive the cell to become more malignant. 
These observations were made in context of Hsp90 inhibition and its effects on 
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cytoskeletal architecture and remodeling during cell motility and cell invasion. Hsp90 
inhibition lead to decreased cell motility associated with a decrease in filopodia, 
lamellipodia and tough cortical actin bundles and resulted in less ruffling. The Hsp90 
inhibition was also associated with a loss of mDia-2 and a decrease in RhoA, both 
necessary for the formation of lamellipodia and generation of contractile force. Hsp90 
inhibition stimulated an increase in the pull down of actin in the soluble fraction with 
Hsp90. These observations suggested an increased interaction of Hsp90 with the soluble 
form of actin (G-actin) and αB-crystallin upon Hsp90 inhibition, which might be 
responsible for the decreased actin tread-milling at the cell periphery. Actin-ECFP and 
actin-EYFP showed a 50% reduction in FRET when inhibited with 17-AAG, and 17-AAG 
treatment resulted in an 80% decrease in inverse cell invasion for MDA-MB-231-GFP 
cells. Inhibition of Hsp90 also leads to a decrease in surface Hsp90 expression109. In light 
of the many advances in studying extracellular Hsp90, several questions remain: How 
do the extracellular cues communicate with the exosomal trafficking machinery to send 
Hsp90 out of the cell? Do the extracellular cues selectively cause Hsp90 secretion and 
leave other exosome-housed proteins behind or do they simply trigger secretion of the 
exosome vesicles as a whole? What percentage of total intracellular Hsp90 gets secreted?  
One of the most important questions that we can ask pharmacologically is 
whether the surface expression of Hsp90 can be exploited to increase the safety 
threshold of future Hsp90 inhibitors.  Our laboratory has explored the hypothesis that 
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expression of surface Hsp90 may contribute to the tumor selectivity of many Hsp90 
inhibitors. This hypothesis was driven by our data using cell impermeable Hsp90 
inhibitors tethered to fluorophores showing that a portion of ectopically expressed 
Hsp90 was reinternalized causing drug accumulation110. By extension of this 
observation, it is conceivable that many leading inhibitors of Hsp90 preferentially enter 
tumor cells through a similar mechanism and may have been fortuitously optimized to 
do so. Such a statement is not without possibility. From our own experience in the 
discovery of Hsp90 inhibitors, although our initial high throughput leads were 
identified by elution of native Hsp90 bound to an ATP affinity column, all molecules 
were subsequently evaluated for biological activity in cell-based assays41. These assays 
comprised a combination of growth inhibition and evidence of the mechanism of action 
including inhibition of Her2 expression, induction of Hsp70, Akt and S6 
phosphorylation. Generally at this stage compounds that caused overt cell toxicity 
would have been considered second tier and not pursued further. Such a path would 
have most likely have been pursued by other groups developing Hsp90 inhibitors. It 
will therefore be interesting to test whether Hsp90 inhibitors that have higher cLogP 
values, and are thus more freely diffusible, are more toxic to normal cells compared with 
our current armamentarium of clinically active Hsp90 inhibitors. This finding would 
have great significance because the development of Hsp90 inhibitors that only penetrate 
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cells through interactions with surface Hsp90 could have vastly improved safety profiles 
enabling the therapeutic window of this class of drugs to be extended.    
1.5 Combination Therapy 
Typically when Hsp90 inhibitors are successively dosed to animals bearing 
human tumors, the tumors stop growing. However, when the inhibitor is withdrawn the 
tumors tend to start growing again41. Generally the same phenomenon occurs in patients 
with solid tumors being treated with a variety of structurally unrelated Hsp90 
inhibitors. These observations are consistent with the role of the protein in maintaining 
tumor growth and suppression of these pathways by Hsp90 inhibitors. For these reasons 
Hsp90 inhibitors may have limited use as a monotherapy. Although, more recent 
observations suggest that certain tumor types may be more responsive to Hsp90 
inhibition than others and monotherapy may be sufficient to promote tumor reduction, 
and even cellular death.  In recent Phase II studies with ganetespib alone, an 
encouraging response rate of 50% in NSCLC patients whose tumors contained ALK 
translocations was observed111.  Instead there is however great excitement in the field for 
using Hsp90 inhibitors in combination with either existing chemotherapeutics or more 
cutting edge drugs like Herceptin, lapatinib or Gleevec. Fadden et al shows that a 
combination of the drug SNX5422 and Herceptin not only shrinks the tumors 
dramatically and persistently (even after withdrawal), but it is also synergistic41.  The 
argument for combination therapy is in the evidence that genome sequencing of human 
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cancers reveals numerous driver mutations within any one individual cancer112,113. 
Intratumor heterogeneity may foster tumor evolution and adaptation and hinder 
personalized-medicine strategies that depend on results from single tumor-biopsy 
samples114. Hsp90 inhibitors can play a unique role in preventing drug resistance in 
tumors because oncogenes rely heavily on Hsp90 to chaperone their otherwise unstable 
conformation due to their mutations. This dependence has been termed oncogene 
addiction. Because numerous mutant oncoproteins are “addicted” to Hsp90 activity, an 
inhibitor to Hsp90 has the ability to affect multiple targets and pathways, which can 
prevent oncogene switching, a major mechanism for developing resistance115,116.  
Hsp90 inhibitors have the potential to circumvent or diminish the drug 
resistance seen in the use of target-based therapies, but because cancers evolve, 
resistance to Hsp90 inhibition is also a real possibility. However, the silencing of co-
chaperones such as p23, Aha1, or Cdc37, has been shown to cause dramatic sensitization 
to Hsp90 inhibition117-119. Because Hsp90 inhibition allows the trimerization and 
activation of HSF1, and because elevated HSF1 is linked to stages of oncogenesis, there 
are efforts to find inhibitors to HSF1 that can be used in conjunction with Hsp90 
inhibitors to minimize the negative effects of Hsp90 inhibition120,121. As a result of HSF1 
activation, Hsp70 transcription is dramatically upregulated, which is often used as 
readout in cell based assays for efficacy of an Hsp90 inhibitor. However, Hsp70 
induction is another chaperone that can drive oncogenesis in many tumors. Researchers 
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have shown a therapeutic value for targeting Hsp70 because tumors overexpress the 
inducible form over the constitutive form122. Therefore, combination therapy that 
inhibits both Hsp90 and the inducible Hsp70 could be formidable method of treating 
cancer by eliminating the unwanted effect of Hsp70 induction. 
1.6 Conclusions 
While some are still not cognizant to the advances of Hsp90 inhibitors in the 
clinic, others, including members of the Hsp90 community, still question whether or not 
any of the now 17 Hsp90 inhibitors will successfully exit clinical trials and enter the 
market.  We think the day will come that Hsp90 inhibitors will be commonplace in the 
clinic and that in the oncological application of Hsp90 inhibitors, these drugs will be 
used as first line chemotherapeutics in combination with other potent anti-cancer 
therapies to prevent or prolong the development of drug resistance. In the immediate 
term, combination therapy involving an Hsp90 inhibitor and cutting edge targeted 
therapies clearly holds the greatest promise. If the consistent synergisms in efficacy and 
tumor elimination observed in animal combination studies with drugs such as Herceptin 
hold true in human trials maybe we are well on the way to seeing actual “cures” rather 
thinking about merely halting disease progression over the shorter term. Beyond 
combination therapy, as we have discussed, other aspects of Hsp90 biology may render 
it even more druggable. Exploring the differences in Hsp90 between cancer cells and 
normal tissues may reveal additional strategies on how to target Hsp90 and how to 
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improve its therapeutic window. One of these in our sights is the role of ectopically 
expressed Hsp90 in metastatic progression. Although yet to be demonstrated in human 
biopsy samples, clearly, if there is a correlation between expression of ectopic Hsp90 and 
metastatic progression, this is likely to be of both diagnostic importance as well as 
therapeutic. If expression of ectopic Hsp90 correlates with poor outcomes it could be 
used as an early biomarker to discriminate indolent forms from aggressive disease. We 
are particularly excited by the prospect of developing Hsp90 inhibitors that only target 
ectopically expressed Hsp90 as a means to improve the selectivity of Hsp90 inhibitors 
and deliver tumor-killing payloads to tumor cells. On top of all these tangible 
possibilities for extending Hsp90s therapeutic potential is the co-chaperone/chaperone 
machinery of associated proteins regulating and regulated by Hsp90. Once bona fide 
clients are established and validated, one could envision strategies that could selectively 
inhibit these protein-protein interactions, thus potentially making Hsp90 therapy highly 
targeted and disease specific. 
Finally, from a pharmacologist’s perspective, there are lessons to be learned from 
the development of Hsp90 as a cancer target that are pertinent to 21st century drug 
discovery. Clearly, new therapies to treat cancer are not always going to be obvious as 
has been the case in the past i.e. one must not assume that a “hall mark of cancer” 
involves a point mutation and that alone signifies a usable target. Not all targets are 
going to be “Gleevec type stories”. If we make the assumption that this is the case we are 
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likely to miss the boat on some great opportunities. A second lesson is that although an 
Hsp90 drug has yet to be brought to market, there is clearly a ground swell of 
independent data that strongly indicate that this will happen soon, despite some side 
effect concerns such as retinal toxicities. This ground swell is self-evident in the form of 
the numbers of independently derived inhibitors that are currently being advanced 
clinically. Within these independent paths we count an extraordinary six distinct 
structurally diverse scaffolds upon which the current clinical armamentarium of Hsp90 
inhibitors is currently derived. In future drug discovery efforts involving 
unconventional targets where we don’t have obvious genetic data to validate a target we 
should look for similar trends to assure pharmaceutical companies that such targets 
should not be ignored.
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2. Experimental Procedures 
2.1 Studies with HSP90 antibodies 
MCF7 and MCF10A cells were cultured and fixed in wells using 4% PFA/PBS. 
Successively, cells were incubated in blocking solution (5% goat serum, 0.2% Na Azide, 
PBS) with or without 0.3% Triton X-100 for 1 hour. After blocking with or without the 
detergent, cells were incubated with a polyclonal antibody for Hsp90 at 1:100 (sc-7947, 
Santa Cruz Biotechnology, Santa Cruz, California). Cells were sequentially incubated 
with a goat-anti-rabbit Alexa Fluor 488-conjugated antibody at 1:1,000 (A-11008, Life 
Technologies, Grand Island, New York). Cells were imaged using the Olympus IX 71 
epifluorescence microscope. To evaluate ectopic expression of HSP90, HSP90 antibody 
was incubated with live MCF7cells (2.5 hours), then 100 nM of HS-27 was added. 
Concurrently, cells were stained with DAPI and goat-anti-rabbit Alexa Fluor 568 
secondary antibody (A11011, Life Technologies, NY) at 1:1,000 and incubated the cells 
for one hour at 37°C. Cells were washed in PBS and imaged using the Olympus IX 71 
epifluorescence microscope. Ratios of cells that retained HS-27 at the cell periphery to 
cells that internalized HS-27 was calculated and plotted against the antibody mass.  
2.2 Anion exchange chromatography 
Samples from either cell or tissue lysates underwent buffer exchange using 30K 
or 10K filter devices. Lysis buffers were exchanged for 25 mM Tris-HCl and 1 mM DTT. 
Samples were centrifuged (13,000 rpm, 10 minutes), then passed through a 0.2 µm 
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syringe filter. Next the supernatants were loaded onto a Pharmacia mono Q anion-
exchange SMART column (0.1 X 1.0 cm) that has been previously equilibrated in 25 mM 
Tris-HCl, 1 mM dithiothreitol buffer, pH 7.4 as described123. The column was eluted 
using a linear salt gradient over 80 minutes (100 µL/minute) to 1 M NaCl in the same 
buffer. Samples were fractionated into an opaque plate that was read for fluorescence on 
the multi label plate reader. Peak fractions of fluorescence were passed over a cleavable 
affinity resin to purify Hsp90 as described47. 
2.3 IVIS Kinetic mouse imaging 
All protocols using mice were approved beforehand by the IACUC at Duke 
University and strictly adhered to throughout the studies. SCID mice bearing MDA-MB-
468 tumors were anesthetized with ketamine. Mice received tail vein injections or 
abdominal injections and imaged post injection at the indicated time using an IVIS 
Kinetic imager (Caliper Life Science, MA) as part of the Optical Molecular Imaging and 
Analysis shared resource in the Duke Cancer Institute. The following filters were used 
for the corresponding small molecule inhibitors (emission/excitation): HS-27 (468/GFP), 
HS-105 (468/GFP), HS-69 (640/Cy5.5), HS-70 (745/ICG).  
2.4 Tissue Harvest and Analysis 
The following mouse tissues were taken immediately post mortem: blood, brain, 
eyes, heart, kidney, liver, lung, spleen, and tumor. With the exception of the blood, the 
tissues were rinsed in PBS and blotted followed by image analysis using the IVIS kinetic 
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imager. Tissues were stored on dry ice or at -80°C. For analysis of tissue lysates using 
SMART mono Q fractionation and multi label fluorescent reader, tissues were dounced 
in mono Q buffer (25 mM Tris-HCl, 1 mM DTT). We centrifuged the samples and 
transferred supernatants to be analyzed for fluorescence and protein concentration. 
2.5 Fluorescence spectroscopy of drug uptake 
SCID mice bearing MDA-MB-468 tumors were anesthetized with ketamine and 
received tail vein injections of drug. Using an optical spectroscopy instrument and a 
fiber optic probe the fluorescence spectrum of the FITC-conjugated drug was measured 
in vivo at 6, 24, 48, 72 and 96 hours post injection124. With optical spectroscopy, tissue is 
illuminated using light of interest and the reflected light is analyzed to study the 
morphology and biochemical composition of the underlying tissue. The pen-shaped 
fiber optic probe has a diameter of approximately 2 mm and was placed in gentle 
contact with the tumor or adjacent normal site. Incident light at 490 nm corresponding to 
FITC excitation was delivered through the probe into tissue and resulting longer 
wavelength fluorescent light was collected. Although 490 nm does not correspond to 
maximal absorption by FITC, this wavelength was used to minimize fluorescent 
contributions from flavins (FAD) which fluoresces in the same wavelength range. 
Measured fluorescence spectra were corrected for tissue absorption and scattering using 
an intrinsic fluorescence recovery model described in the literature125. Briefly, the model 
calculates the tissue optical properties that are a function of light scattering and 
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absorption and uses these properties to correct distortions in the measured fluorescence. 
The intrinsic fluorescence model has been shown to accurately recover fluorophore 
concentrations in tissue-mimicking phantoms126. In addition, the intrinsic fluorescence 
calculated using this model has been used to monitor intra-tumor drug concentrations in 
vivo and shown to be strongly correlated with concentrations measured using HPLC127. 
Because optical spectroscopy measures wavelength-dependent fluorescence, the 
background fluorescence can be accurately measured prior to injection. This allows 
monitoring of the fluorophore concentration in vivo and determination of when the 
fluorescent tether has cleared from the tumor. 
2.6 Active Hsp90 depletion using affinity resin chromatography 
MDA-MB-468 cell lysate was diluted to 1 mg/mL in low stringency wash buffer 
and 1 mL was added to 1 mL of the Hsp90 affinity resin at 50% slurry. For three 
consecutive washes fresh resin was used and 25 µL of flow through (< 3%) was set aside 
for flow through analysis. The resin was washed thoroughly with low stringency wash 
buffer and then Hsp90 was eluted off with 10% SDS. Both flow through and resin 
samples were characterized by 1D SDS-PAGE and silver staining. In a separate 
experiment, flow through and resin samples were incubated with 100 nM HS-27 and 
then washed using a 10K kDa filter. Samples were concentrated and analyzed on a 
multilabel plate reader for fluorescence.  
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For the more through-put assay of analyzing active and inactive Hsp90, cell and 
tissue lysates were diluted in low stringency wash buffer to 0.1 mg/mL and 100 µL was 
added to 300 µL of prewashed, 50% slurry Hsp90 affinity resin in wells of a 96-well plate 
with 0.2 µm PDVF membranes on the bottom. The resin was washed three times and the 
flow through was captured and transferred to the next well of virgin resin. The resin 
samples were incubated with 5X SDS sample buffer and the flow through was 
concentrated to 50 µL boiled with 5X SDS sample buffer. All samples were subsequently 
run out by gel electrophoresis, transferred to PVDF and immunoblotted for Hsp90.  
2.7 Ex vivo cell treatment and injection into mice 
MDA-MB-468 cells were treated with 5 µM β-escin for 5 minutes. Cells were 
harvested and treated with either 10 µM HS-70 or PBS. Cells were counted and aliquots 
of 10 million to 10 thousand cells were made in 200 µL of saline. SCID mice were 
anesthetized with ketamine and received two flank injections of the treated cells and the 
control cells. Mice were imaged using the IVIS kinetic imager and average radiant 
efficiency was measured.  
2.8 125I-labeled Hsp90 inhibitor treatment of cells 
Cells were permeabilized by treatment with 5 µM β-escin for 5 minutes. 
Competition experiments were performed by treatment of cells with 1 µM of HS-10 for 5 
minutes prior to exposure to the [125I]HS-111. β-escin and HS-10 were washed away and 
then cells were incubated in 5 mL of medium with the [125I]HS-111 that had about 10 µCi 
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of activity per 10 cm dish of cells for 45 minutes. Cells were washed extensively with 
PBS and then lysed on an ethanol/dry ice bath and harvested in 25 mM Tris buffer and 
centrifuged. Supernatants were fractionated on a Pharmacia mono Q anion-exchange 
SMART column and fractions were counted using a PerkinElmer 1480 Wizard 3 gamma 
counter (Turku, Finland) for 30 seconds per fraction sample. 
2.9 Immunoblotting and treatment of cells with fluor-tethered 
inhibitors 
MCF7, MCF10A, BT474, MDA-MB-468, and Huh7 cell lines were cultured under 
standard conditions. For Western and biochemical studies, following treatments, cells 
were washed in PBS and flash frozen on dry ice/95% ethanol and extracts prepared as 
described previously47. Western blots were quantified using ImageJ software (National 
Institutes of Health, Bethesda, Maryland). All protein concentrations were determined 
by Bradford assay. For cell permeabilization, cells were washed with PBS and incubated 
in 5 µM β-Escin in Rigors buffer solution at room temperature then treated with 100 µM 
HS-27128. For quantification of fluor-probe uptake, lysates were prepared from washed 
cells treated with the probe and immediately analyzed for fluorescence on a Victor X2 
2030 multilabel reader (Perkin Elmer, Waltham, Massachusetts) using either 
excitation/emission pairs of 485/535 (fluorescein) or 635/660 (nIR). For fluorescent 
microscopy, following washing in PBS, cells were imaged in culture using an Olympus 
IX 71 epifluorescence microscope, and images were acquired using an Olympus DP70 
digital camera. Cells were also counterstained with DAPI. 
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2.10 Determination of inhibitor affinity using immobilized ATP 
ATP resin was prepared as described previously47. All affinity measurements 
were determined against lactating pig mammary gland Hsp9047. Briefly, mammary 
gland extract was mixed with ATP resin at ratio of 5 grams of tissue to 1 mL of resin. 
Following washing, the charged resin was transferred by 50 µL aliquots on a PVDF 
membrane filter plate. Various tethered Hsp90 inhibitors were added at the indicated 
concentrations and the filter plates were placed on top of a microtitre plate and 
centrifuged (1 min, 3,000 X g). Following elution with the nucleotides, the eluted 
proteins were characterized by 1D SDS-PAGE and silver staining. The gels were 
analyzed by densitometry and regions of the gel containing Hsp90 excised analyzed in a 
4700 AB systems MALDI TOF TOF mass spectrometer as described47 . 
2.11 Flow cytometry of cultured cells and excised tissues  
Cells were seeded into 24-well plates at 1 x 10^5 cells/well the day before the 
assay. β-escin at 5 µM was prepared with HS-27 at 100 nM. Following media aspiration 
and washing with PBS, the cells treated with 0.05% Trypsin/EDTA for 5 minutes then 
harvested by centrifugation (1,200 rpm, 5 minutes). Cells were resuspended in 1% 
BSA/PBS buffer and analyzed by flow cytometry on a BD FACSCalibur using CellQuest 
software (Becton Dickinson and Company, San Jose, California). In competition 
experiments performed cells were first incubated with HS-10 (10 µM, 5 minutes), 
followed by aspiration and incubation with HS-27.  For flow analysis of HS-27 uptake 
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into tumors and other tissues, the excised tissues were harvested, minced and digested 
with trypsin as described129. 
2.12 Heat shock treatment 
Cells that underwent heat shock treatment were incubated at 42°C for 1 hour and 
returned to an incubator at 37°C for 18 hours.  
2.13 pH effect on HS-27 fluorescence 
 Phosphate buffered saline was adjusted to pH 1 to 14 and 5 µM of HS-27 was 
added to each condition and fluorescence was measured in an opaque plate on a 
multilabel plate reader with the filter pair of 485 excitation and 535 emission. 
2.14 Mass Spectrometry Protein Identification 
Visible bands were excised from the gel manually and cut into small pieces 
approximately 1mm x 1mm.  These gel pieces were washed (x3) with water, then 
washed (x2) with 1:1 acetonitrile: 100mM ammonium bicarbonate.  To further prepare 
the gel pieces for digestion, the gel pieces were then dehydrated in 100% acetonitrile.  
After removing all acetonitrile, 30µL of porcine trypsin (Promega) at a concentration of 
20 µg/mL was added to the gel pieces.  The gel pieces were then kept on ice for 
approximately 1 hour to allow for the trypsin to remain inactive as it enters the gel.  
Following this, the gel pieces were incubated at 37°C overnight (approximately 12-16 
hours).   Following digestion, the supernatant was transferred to a second tube, and 
acetonitrile was added to the gel pieces to complete the extraction of digested peptides.  
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This extract was added to the first supernatant and this combined solution, containing 
the extracted peptides was frozen and lyophilized.  The peptides were resuspended in 5 
µL of 1:1 acetonitrile:0.5% aqueous formic acid immediately prior to spotting on the 
MALDI target.     
For MALDI analysis, the matrix solution consisted of alpha-cyano-4-
hydroxycinnamic acid (Aldrich Chemical Co. Milwaukee, WI) saturating a solution of 
1:1:0.01 acetonitrile: 25mM ammonium citrate: trifuoroacetic acid.  Approximately 0.15 
µL of peptide solution was spotted on the MALDI target immediately followed by 0.15 
µL of the matrix solution.  This combined solution was allowed to dry at room 
temperature.  MALDI MS and MS/MS data was then acquired using the ABI 4700 
TOFTOF Mass Spectrometer (Applied Biosystems Inc., Framingham, MA).  Resultant 
peptide mass fingerprint and peptide sequence data was submitted to the NCBI 
database using the Mascot search engine to which relevance is calculated and scores are 
displayed. 
2.15 Mammary Gland Tissue Collection 
Lactating mammary tissue was collected at the local abattoir from 2 Yorkshire 
sows ages 1.5-and 2.5 years.  The mammary tissue of only active glands was dissected 
away from skin and underlying muscle, flash frozen and stored at -80°C until processed.  
Weaning occurred on day 7 of lactation for sow 1, 2 hours prior to collection and on day 
18 of lactation for sow 2, 18 hours prior to tissue collection.  
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Table 2: Lactating pigs’ biographical data 
 Date 
Harvested 
Breed Age (mo) Time from wean 
to euthanasia (hr) 
Litter 
size 
Days 
lactating 
1 2/01/2010 Yorkshire 17 18 8 18 
2 8/31/2010 Yorkshire 30 2 5 7 
 
2.16 Mouse Tissue Extraction 
Adult male mice (Mus musculus (house mouse) black 6 strain) were CO2-
asphyxiated and sacrificed. The organs of interest (i.e. pancreas, heart, spleen, kidney, 
skin, brain, colon, lung, testes, skeletal muscle, liver, adipose, and eye) were quickly 
excised and washed in ice-cold phosphate-buffered saline. The organs were then frozen 
in liquid nitrogen and the tissue ground in liquid nitrogen with a mortar and pestle. The 
liquid nitrogen was allowed to evaporate off and the mass of the tissue was measured. 
Immediately afterwards, 2.5 X the volume (mL) of extraction buffer [50 mM HEPES, 60 
mM MgCl2, 60 mM  KCl, 0.2% NP-40, 1 mM DTT, 1 µM Microcystin (Cayman Chemical 
Company), Complete Mini protease inhibitor cocktail (Roche), pH 7.4]  was added to the 
powdered tissue (gram). The tissue samples were subsequently centrifuged at high 
speed and the supernatants collected to combine with the affinity resin columns.  The 
protein concentrations were determined for each tissue by Bradford analysis and the 
tissue sample divided in half.  
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2.17 Resin Binding 
Before binding to the resin, if competition was performed, then half of each 
sample was pretreated with 1 mM of HS-10 for 1 hour at room temperature. Following 
the pretreatment, all samples were tumbled with 100 µL of 50% slurry of the Hsp90 
affinity resin. After 1 hour of tumbling, the resin was washed 3 X with a low stringency 
wash buffer [50 mM Tris-HCl, 60 mM MgCl2, 60 mM KCl, 10 mM Citrate, 1 mM DTT, 
pH 7.4]. After the final wash, the buffer was completely aspirated and replaced with 30 
µL of 25 mM dithionite in 100 mM phosphate buffer solution pH 7.4 and tumbled for 1 
hour at room temperature. Subsequently, the resin was pelleted and the cleaved linker 
with the protein was removed and subjected to 2 % SDS denaturation for 10 min at 90°C.  
2.18 Protein gel electrophoresis and silver staining 
SDS protein samples were loaded in Criterion precast gels (BioRad), 4-15% Tris-
HCl and separated at 120 V. Gels were then fixed in 10 % methanol and 5% acetic acid 
for 20 minutes. Afterwards, the gels were washed 4 X in H2O, incubated in 0.2 g 
thiosulfate/500 mL of H2O for 90 seconds and then washed 3 X in H2O. The gels were 
then incubated in 0.9 g silver nitrate/500 mL of H2O for 20 minutes and washed 3 X in 
H2O and finally incubated in a developer solution of 10 g potassium carbonate, 20 mL of 
the thiosulfate solution, 0.02 % formaldehyde/500 mL of H2O. The reaction was 
quenched with 10% methanol and 5% acetic acid just as the background started to stain.  
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2.19 Pig mammary protein extraction 
Frozen pig mammary tissue was ground in liquid nitrogen and stored at -80°C. 
Pig tissue mass was measured (g) and then 2.5 X volume (mL) of extraction buffer  [50 
mM HEPES, 60 mM MgCl2, 60 mM  KCl, 0.2% NP-40, 1 mM DTT, 1 µM Microcystin 
(Cayman Chemical Company), Complete Mini protease inhibitor cocktail (Roche), pH 
7.4] was added and homogenized on a laboratory blender. The homogenate was 
centrifuged at 35,000 rpm for 45 minutes at 4°C, and then the supernatant was filtered 
over silica wool to purify from solid materials. The protein extract concentration was 
determined by Bradford analysis.  
2.20 Thermofluor Assay 
SYPRO orange (Molecular Probes, Eugene, OR) was diluted 1:1000 in 25 mM 
HEPES, 5 mM MgCl2, 10mM KCl (pH 7.5), and purified Hsp90 from the resin or Hsp90 
harvested from the flow through after mono Q fractionation was then added to a final 
dilution of 0.04 mg/ml. Compound or DMSO was then added at the specified 
concentration and each sample was added as a minimum of three replicates to a 384 
well-plate (BioRad, Hercules, CA). A melt curve protocol (25°C to 90°C, increasing 0.5°C 
and a plate reading every 30 seconds) was run on a CFX384 TouchTM Real-Time PCR 
Detection System (BioRad, Hercules, CA) to determine the midpoint of the protein 
unfolding transition or Tm. GraphPad Prisim4 (La Jolla, CA) was used to normalize the 
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melt curve and to calculate the first derivate of the melt curve, with the steepest point of 
the slope being the Tm.  
2.21 Cell culture 
BT474 cells were maintained in RPMI-1640 supplemented with 10% fetal bovine 
serum and incubated at 37°C in 5% CO2. MDA-MB-468, MCF7, SKBr3, Huh7 and HEK 
293T cells were maintained in DMEM supplemented with 10% fetal bovine serum and 
incubated at 37°C in 5% CO2. MCF10A cells were maintained in DMEM/F12 (1:1) 
supplemented with 5% horse serum, 20 µg/mL EGF, 500 ng/mL hydrocortisone, 100 
ng/mL cholera toxin, 10 µg/mL insulin and incubated at 37°C in 5% CO2. 
2.22 Determination of tissue affinity for HS-27 
Cell lysates and tissues were harvested and protein concentration was measured 
by Bradford assay. 2000 µg of total protein was added to 96-well 10K cutoff filter plates 
and the indicated amount of HS-27 was added and incubated for 15 minutes with gentle 
agitation. Sample wells were subsequently washed with low stringency wash buffer 
until negligible fluorescence was observed in the flow through. Each sample well was 
then punctured with a pin to allow samples to flow through to an opaque catch plate, 
wherein fluorescence was measured on a multilabel fluorescent plate reader using the 
485 excitation and 535 emission filter pair. 
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3. Extracellular Hsp90 for tumor detection 
Hsp90 inhibitors have demonstrated unusual selectivity for tumor cells despite 
its ubiquitous expression. This phenomenon has remained unexplained but could be 
influenced by ectopically expressed Hsp90 in tumors. We have synthesized novel Hsp90 
inhibitors that can carry optical or radioiodinated probes via a PEG tether. We show that 
these tethered inhibitors selectively recognize cells expressing ectopic Hsp90 and 
become internalized. The internalization process is blocked by Hsp90 antibodies, 
suggesting that active cycling of the protein is occurring at the plasma membrane. In 
mice, we show exquisite accumulation of the fluor-tethered versions within breast 
tumors with very high sensitivity. Cell-based assays with the radiolabeled Hsp90 
inhibitor showed picomolar accumulation that was detected by gamma counting . Our 
findings show that fluor-tethered or radiolabeled inhibitors targeting ectopic Hsp90 can 
be used to detect breast cancer malignancies through non-invasive imaging.   
3.1 The breast tumor detection paradigm 
The current paradigm for detection and treatment of breast cancer is based on 
clinical evaluation and anatomic imaging, usually with mammography or less 
commonly breast magnetic resonance imaging (MRI), followed by biopsy and surgery or 
surgery plus radiotherapy. Other imaging modalities, such as ultrasound or position 
emission tomography (PET), are not routinely used for screening although they have 
specific indications and potential130. While both mammography and MRI demonstrate 
 44 
excellent sensitivity for detecting tissue abnormalities, they lack sufficient specificity for 
unequivocally distinguishing malignant tissue from benign tissue131. The question 
remains as to whether pre-malignant molecular markers can be used non-invasively to 
detect aggressive cancers. 
It is clear that anatomic changes are not the earliest cancer-related 
transformations. Instead, breast cells with malignant and lethal potential are 
characterized early on by activated oncogenic signaling nodes. These signaling nodes 
have been classified into a broad set of characteristics termed the “Hallmarks of Cancer” 
and are candidate molecular markers of malignant behavior2. Unfortunately, these 
signaling nodes have been difficult to detect in vivo, particularly when confined to small 
clusters of cells, as in early stage disease. To date, strategies to visualize these signals in 
vivo, such as using 18FDG-PET to detect increased glucose uptake, have not achieved the 
sensitivity or specificity required to appreciably improve breast cancer screening and 
diagnosis132.  
Hsp90 is a signaling node that could be exploited as a diagnostic molecular 
marker to distinguish malignant breast cells from normal tissues133. Hsp90 has an 
essential role in cellular homeostasis by chaperoning client proteins. Over 400 putative 
Hsp90 clients have been identified and many of these regulate signaling pathways 
governing cellular growth and differentiation46,66,68,134,135. Hsp90 and its family members, 
Grp94 and TRAP1, contain an N-terminal ATP-binding domain with ATPase activity 
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that is necessary for cellular function33. Hsp90 is regulated both translationally and post-
translationally, the latter affecting both ATPase activity and intracellular location14. 
Direct evidence for Hsp90’s participation in oncogenic protein folding/stability in vivo 
comes from studies with Hsp90 inhibitors that bind competitively to its ATP-binding 
domain resulting in the degradation of its oncogenic clients41,136,137. This phenomenon has 
also been demonstrated in human tumor biopsies from patients undergoing Hsp90 
inhibitor therapy138. To date, there are 17 different Hsp90 inhibitors targeting its ATP-
binding site in clinical development for multiple indications in cancer52,53,138,139. 
Recent studies have linked high expression of Hsp90 with poor prognosis in 
malignant breast tumors58,59.  The role of Hsp90 in mediating malignant behavior may be 
the result of oncogene driven factors that alter its normal cellular behavior56. 
Hyperactivation is postulated to result in an increased affinity for ATP and Hsp90 
inhibitors and the expression of ectopic Hsp9097,140. If oncogenically activated Hsp90 
precedes malignant behavior in vivo, we reasoned that this could be used 
diagnostically96,104,106. We therefore developed a series of Hsp90 inhibitors tethered to 
fluorophores or radioiodine to detect Hsp90 in vivo. When injected into mice bearing 
human breast tumors, the fluorophore versions are exquisitely targeted to tumors. We 
show that this targeting is achieved through interactions with ectopic Hsp90, which is 
undergoing active internalization along with the bound probes. This finding suggests 
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new roles for Hsp90 in which the protein is not only trafficked to the plasma membrane 
but also reinternalized. 
3.2 Synthesis and Development of Probes Selectively Targeting 
Ectopic Hsp90 
We have also developed a cleavable tethered Hsp90 inhibitor and demonstrated 
its use as an affinity resin47.  When bound to the tethered ligand, Hsp90 could be 
recovered along with one of its established oncogenic clients, Her2, in a competitive 
manner (Figure 42). To extend our tethered ligands utility, we synthesized several 
versions tethered to a variety of fluorophores and other molecules to facilitate the 
detection of Hsp90 in vivo (Figure 2, Appendix A and Table 3).    
 
Figure 2: Generic structure of tethered Hsp90 inhibitors 
 
 
 
 
 47 
In binding studies against immobilized ATP, the tethered inhibitors showed 
reduced affinity for native Hsp90 (Kd HS-27, 288 nM; HS-69, 49 nM; HS-70, 42 nM) in 
comparison to the parent compound (HS-10, 3 nM) ( 
Table 3 and Figure 3)41,141.  Proteins from a pig mammary gland were loaded onto 
an ATP media resin and eluted with HS-10 or HS-27 (n = 3, ±SEM).  
 
 
 
Figure 3: Hsp90 affinity for HS-10 and HS-27 
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Despite some reduction in affinity, the addition of the tethered components was 
found to increase specificity by eliminating binding to Grp94 (Figure 4). Both non-
conjugated HS-10 and PU-H71 showed non-selectivity between Hsp90 isoforms by 
eluting both Hsp90 (bottom arrow) and Grp94 (top arrow). Grp94 is no longer eluted 
when molecules are tethered to HS-10 at 100 µM. HS-105 is a control compound with no 
ligand for Hsp90. 
 
 
Figure 4: Hsp90 selectivity with tethered Hsp90 inhibitors 
Previous work had also shown that the addition of the tether at the ortho-
position of the parent ligand reduced the specificity towards recombinant and native 
TRAP147. These findings suggest that the added steric bulk due to the presence of the 
tether and added fluorophore, for example, interferes with the ATP-binding site of 
Grp94 and TRAP1, but not Hsp90. Similar specificity was also observed by adding 
various non-fluorescent molecules to the tethers, such as ferrocene, iodinated 
benzylamine or an additional Hsp90 inhibitor, to create a bifunctional inhibitor (Figure 
4, Table 3). 
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Table 3: Hsp90 and Her2 tethered inhibitors: names, descriptive features and 
structures for compounds 
Designation 
name 
Feature Structure 
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Next, we evaluated the specificity of the fluor-probes in several transformed cell 
lines by fluorescent microscopy. These cell lines were selected to represent each of the 
major breast cancer classification schemes: Her2+, ER+, triple negative breast cancer, and 
a non-tumorigenic immortalized breast epithelial cell line (Table 4).  
Table 4: Breast cell line classifications 
Cell line subtype ER* PR* Her* source tumor type 
BT474 Luminal + + + primary tumor invasive ductal carcinoma 
MCF7 Luminal + + - pleural effusion metastatic adenocarcinoma 
MCF10A Basal B - - - reduction mammoplasty fibrocystic disease 
MDA-MB-468 Basal A - - - pleural effusion metastatic adenocarcinoma 
 
Figure 5 shows that HS-27 at 100 µM is internalized by breast cancer cell lines, 
which correlate to the established malignancy of the cell lines (scale bar, 50 µm). 
Remarkably, HS-27 does not label Huh7 cells, a hepatocarcinoma cell line, despite the 
latter cell line having higher total cellular levels of Hsp90 as determined by 
immunoblotting (Figure 6).  
Figure 5: Tissue culture cell lines demonstrate variable responses to HS-27 
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Immunoblotting of Hsp90 and Her2 was performed in several cancer cell lines. 
Cell lysates were harvested and analyzed by Western blotting. Hsp90 was highest in 
Huh7 cells and the same amongst BT474, MCF7, and MDA-MB-468 and less in the non-
tumorigenic breast cancer cell line MCF10A. Additionally, only BT474 cells 
demonstrated the presence of Her2 in total cell extracts as expected (Figure 6).  
 
Figure 6: Immunoblots of Hsp90 and Her2 in cell lines 
Time course studies at 100 µM HS-27 and titration studies evaluated at 60 
minutes showed HS-27 uptake is variable between breast lines in the following order 
MCF10<<<MCF7<MDA-MB-468<BT474 despite having approximately equivalent levels 
of total Hsp90 among the latter three, (n = 3, ±SEM) (Figure 7). Interestingly, this uptake 
order correlates with the relative tumorigenicity of the cells to form tumors in SCID 
mice142.  
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Figure 7: Titration and time course studies of HS-27 in cell lines 
Analysis of Her2 levels in BT474 cells show that, once internalized, HS-27 is 
active as an Hsp90 inhibitor and uptake (green) inversely correlates with Her2 
degradation (black) (Figure 8).  
 
Figure 8: HS-27 uptake in BT474 cells inversely correlates to Her2 degradation 
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Figure 9: Flow cytometry reveals that HS-10 competes HS-27 in a dose 
dependent manner in breast cell lines 
Competition experiments with the untethered ligand, HS-10 (Figure 9), and 
comparisons with a control compound FITC-tethered lapatinib, HS-42 (Figure 10), 
demonstrate that HS-27 uptake and selectivity for the breast cells is Hsp90-dependent. 
In the case of HS-42, despite sharing a common fluorophore with HS-27, HS-42 (black 
line) was rapidly absorbed with identical kinetics between BT474 (a) and Huh7 (b) cells 
(Figure 10). These findings show that the uptake of the two FITC-tethered inhibitors 
involve different mechanisms that are ligand-dependent. As for HS-42, uptake may 
reflect binding to EGFR, whereas for HS-27, the apparent mechanism is binding to 
ectopic Hsp90. This conclusion is consistent with others who have linked extracellular 
Hsp90 with the metastatic potential of various tumor lines, including breast cancer 
cells97,140,143. 
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Figure 10: Comparison of HS-27 and HS-42 kinetics in BT474 and Huh7 cell 
lines 
 Additional data supporting that the tethered Hsp90 inhibitors bind to 
ectopically expressed Hsp90 in breast cell lines came from observations with the 
permeabilizing agents, β-escin and Triton X-100. In the presence of 5 µM β-escin, HS-27 
enters MDA-MB-468 and Huh7 cells. To test whether HS-27 was non-specifically 
labeling permeabilized Huh7 cells, we competed HS-27 binding with a 10-fold excess of 
HS-10, which blocked binding in both cell lines (scale bar, 50 µm) (Figure 11). These data 
suggest that Huh7 cells do not express ectopic Hsp90, but they do contain an internal 
pool of Hsp90 that binds the inhibitor. We also observed other cell lines that were 
unable to internalize HS-27 without permeabilization, including lymphoma cells 
purified from patients with CLL, human peripheral blood mononuclear cells or cultured 
fibroblasts.  
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Figure 11: β-escin permeabilization assay points to the role of ectopic Hsp90 in 
HS-27 internalization 
 57 
 
Figure 12: Anti-Hsp90 antibodies label surface Hsp90 in non-detergent 
conditions in MCF7 
Because of its polar nature, HS-27 would not be predicted to enter cells through 
passive diffusion and the competition studies with HS-10 strongly argue that its 
internalization requires binding to Hsp90 expressed at the surface. Consistent with this 
hypothesis, anti-Hsp90 antibodies were found to selectively stain the surface of the more 
tumorigenic MCF7 cells compared with non-tumorigenic MCF10A cells (scale bar, 50 
µm) (Figure 12). These fixed breast cancer cell lines were treated with or without 0.3% 
Triton X-100 and subsequently stained by immunofluorescence with an anti-Hsp90 
antibody. Cells treated with Triton have intracellular pools that are labeled, while non-
permeabilized cells exhibit exclusive labeling of surface Hsp90.  
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Figure 13: Anti-Hsp90 antibodies block the internalization of HS-27 in MCF7 
cells 
Additionally, when live MCF7 cells were incubated with anti-Hsp90 antibodies 
in the presence of HS-27, the probe is retained at the plasma membrane and no longer 
internalized as shown by co-staining at the surface with the Hsp90 antibody ( 
Figure 13). The first row is the incubation with HS-27 alone and denotes a single 
field observed with different filters. Rows 2 and 3 are separate fields of cells incubated 
with the antibody and HS-27. Row 2 demonstrates peripheral staining of Hsp90 (yellow 
arrow) by both the antibody (red) and HS-27 (green). Row 3 shows cells that are not 
labeled with the antibody and have internalized HS-27 (white arrows) (scale bar, 10 µm) 
(Figure 13).  
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Figure 14: Does-dependent Hsp90 antibody blocking of HS-27 internalization 
Importantly, the Hsp90 antibody used in this experiment targets the C-terminal 
domain of the protein and does not interfere with the HS-27 binding at the N-terminal 
ATP-binding domain (Figure 14). In antibody titration experiments, the retention of HS-
27 at the surface correlates precisely with antibody concentration. At 10 µg/well of 
antibody, the number of cells that retained HS-27 at the surface to those cells that 
internalized HS-27 was almost 1:1, whereas the ratio was 1:4 at an antibody treatment of 
2.5 µg/well (Figure 14). Collectively our data highlight an unrecognized pathway in 
which Hsp90 is not only trafficked to the membrane, but actively internalized. The 
internalization is likely not attributed to general pinocytosis that results in fusion with 
the lysosomes. Lysosomes have internal pHs of <6, and HS-27 consists of an Hsp90 
inhibitor tethered to FITC which loses its fluorescent properties below pH 6.5 (Figure 
15). Additionally, we failed to detect the co-localization of HS-27 with Rab5, a marker of 
early endosomes, by fluorescent microscopy. We posit that the internalization 
mechanism of HS-27 is active endocytosis yet Rab5-independent.  
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Figure 15: HS-27 fluorescence is pH dependent 
As aforementioned, Hsp90 is thought to be constitutively secreted only from 
tumor cells90,98,106. To detect the presence of secreted Hsp90, we added 10 µM HS-27 to 
media harvested from BT474, MCF7 and Huh7 cells, and removed the free probe by 
ultrafiltration. BT474 and MCF7 exhibited substantial recovery of fluorescence compared 
to Huh7, which is consistent with the former cells actively secreting Hsp90 (Figure 16).  
 
Figure 16: HS-27 binds to Hsp90 in the conditioned medium of cultured cells 
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To examine whether extracellular Hsp90 was sufficient to facilitate HS-27 uptake 
into Huh7 cells, MCF7 cells were co-cultured with Huh7 cells and incubated with HS-27. 
Figure 17 shows that the presence of locally secreted Hsp90 from MCF7 cells is not 
sufficient to promote subsequent reuptake into the Huh7 cells. This suggests that Huh7 
cells lack the machinery (e.g. receptor) necessary for the active internalization of HS-27 
bound to Hsp90.  
 
Figure 17: Co-culture of Huh7 and MCF7 cells treated with HS-27 
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3.3 Fluor-tethered Hsp90 Inhibitors are Selective for Active 
Hsp90 in vitro 
Our probes can discriminate between various cell lines, but recent data suggest 
that there are distinct populations of active and inactive Hsp90 within a given cell45,46. To 
test if our probes also discriminate between these cellular pools in vivo, we first isolated 
these pools using affinity chromatography. Briefly, cell extracts from MDA-MB-468 cells 
were passed over virgin immobilized Hsp90 ligand beads three times. The “active pool” 
binds and the “non-active pool” flows through the resin (Figure 18)47. Once separated, 
the resin bound extract and flow through were incubated with HS-27 and unbound 
probe was filtered away. Fluorescence was measured on a multi label plate reader (n = 3, 
±SEM student t-test P value < 0.005). Hsp90 from the resin-bound pool demonstrated 
HS-27 binding that was 15.5-fold higher than inactive Hsp90 in the flow through.  
 
Figure 18: Active Hsp90 depletion using affinity resin chromatography 
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 To further characterize the HS-27 bound active pool of Hsp90, we separated 
either purified Hsp90 (from lactating pig mammary gland) or BT474 cell extracts 
incubated with HS-27 by micro-anion-exchange chromatography. In the extracts from 
the BT474 cells, we expected to see multiple column fractions with fluorescence in the 
breast cancer cell extract, consistent with multiple interactions of active Hsp90 with its 
respective client proteins. However, and in most cases, only a single peak of 
fluorescence was observed, which correlated precisely with the migration of purified pig 
mammary Hsp90 bound to HS-27 (Figure 19a).   
 
Figure 19: Mono Q fractions of HS-27 treated cells and purified Hsp90 
Furthermore, we competed the binding of HS-27 with three structurally distinct 
Hsp90 inhibitors: HS-10, PUH71 and 17-DMAG. MCF7 cells were incubated with the 
non-fluorescein Hsp90 inhibitors, followed by HS-27. Equal competition was observed 
with the three Hsp90 inhibitors compared to the DMSO control treatment (Figure 19b). 
The presence of Hsp90 in the single peak was confirmed after column fractions 
containing fluorescence were passed over the cleavable Hsp90 affinity resin followed by 
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SDS-PAGE, silver staining and mass spectrometry (Figure 20). Collectively, these 
biochemical data strongly argue that the only intracellular target for HS-27 is an active 
pool of Hsp90 that is largely devoid of client proteins. These data are consistent with 
previous work by our laboratory using Hsp90 small molecule affinity resins showing 
that the ligand bound form is not associated in vivo with multiple clients as previously 
thought 47. 
 
Figure 20: Hsp90 protein present in corresponding HS-27 fractions 
We next explored whether the probes could be used to measure acute activation 
of Hsp90 in cells in response to heat stress. We show that heat stress produces a 
consistent 1.2-fold increase in fluorescence eluting in the 49th fraction of MCF7 (a) and 
MDA-MB-468 (b) cell lines (Figure 21).  
 
Figure 21: Mono Q fractions of heat shocked cells treated with HS-27 
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We then examined if the probe could be used to quantify the amount of activated 
Hsp90 distributed in normal tissues by adding HS-27 to homogenized mouse tissue 
extracts and then fractionating the tissue extracts chromatographically. Mouse tissues 
were harvested from BALB/C mice and lysed tissues were incubated with HS-27. After 
clearing away the unbound probe, samples were analyzed by anion exchange 
chromatography. Tissues were ordered from lowest expressing tissues to highest. We 
show that homogenized tissues contain diverse levels of active Hsp90 which also elute 
as a single peak (Figure 22).  
 
Figure 22: Mono Q fractions of mouse tissues homogenates exposed to HS-27 
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The significance of these observations is that non-tumorigenic tissues contain an 
active pool of Hsp90, and in brain, spleen, bladder and kidney the levels were especially 
high. Irrespective of this finding, only intact cells expressing ectopic Hsp90 are capable 
of internalizing the fluor-tethered inhibitors. We suggest that malignant tumor cells 
express ectopic Hsp90 and that this pool of Hsp90 can be used to discriminate 
malignancies in vivo over normal tissues or more benign tumor cells. We also conclude 
that although the probe can reflect the tumorigenic state, the drug-bound version must 
have a low affinity for client proteins in stark contrast to the conclusions reported by 
others46. 
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3.4 Fluor-Tethered Hsp90 inhibitors Specifically Target Human 
Breast Tumors in Mice 
To test if fluor-tethered Hsp90 inhibitors might be exploited to selectively 
visualize malignancies non-invasively, we injected the probes into mice bearing breast 
tumor derived xenografts in their right flanks. With MDA-MB-468 xenografts, we 
detected the tumor mass within 5 minutes post intravenous tail injections either with 
HS-27 or the near infrared (nIR) HS-69 and HS-70 versions in a IVIS Kinetic fluorescent 
imager (Perkin-Elmer, Inc.). In the case of HS-27, the tumor is clearly visible through the 
fur and discriminated from the natural background fluorescence normally observed at 
520 nm (Figure 23). With nIR versions, post injection, the probe was observed in the 
extremities (i.e. ears, nose, and paws) and eyes reflecting the circulating unbound probe 
in the blood pool. This was not visible with the fluorescein versions because of the light 
scattering at 520 nm. 
 
Figure 23: Non-invasive imaging of mouse xenograft tumors after post 
injection of HS-27 or HS-69 
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All fluor-tethered Hsp90 inhibitors demonstrated dose-dependent accumulation 
of the small molecules in the tumors (Figure 24a,b). With HS-27, an 8-fold increase was 
consistently observed over control tumors in mice that did not receive HS-27. With both 
nIR probes, we achieved a 150-fold increase at the tumor site due to the low background 
signal at 660 nm or 800 nm. HS-27 (green), HS-69 (red), and HS-70 (dark red) were 
injected in 1 mg doses into mice and tumors excised. Tumors were compared to non-
tumor areas (left flank) and control tumors (n = 3; ±SEM) (Figure 24c,d).  
 
Figure 24: Dose-dependent uptake and specificity of fluor-tethered Hsp90 
inhibitors 
 69 
Pharmacokinetic studies by various methods show dose dependent uptake of 
either the visible or nIR forms, peaking within the tumor mass by 30 minutes and with a 
detectable signal remaining for up to 72 hours (Figure 25). In the case of Figure 25b, non-
tumorigenic tissues displayed no fluorescence over the course of 96 hours.  
 
 
Figure 25: Dose-dependent uptake and pharmacokinetics of fluor-tethered 
Hsp90 inhibitors 
 
 
 
 
 
 
 
 70 
We specifically looked at earlier time points and different methods of 
administration of HS-27. We found that highly vascularized tissues such as the lungs 
exhibited high fluorescence at earlier time points, but by 30 minutes the signal from non-
specific binding was cleared from the organ (Figure 26a). There was no biological 
difference in HS-27 kinetics, whether we injected the animals intravenously (i.v.) or 
intraperitoneally (i.p.). The liver did show greater accumulation in earlier time points in 
the i.p. injection of HS-27, but again it is quickly cleared from the tissue ( 
Figure 26b).  
 
Figure 26: Pharmacokinetics of HS-27 and effects of the route of administration 
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Figure 27: Flow analysis and mono Q detection of HS-27 and HS-69 in tumors 
As a test of tumor selectivity in vivo, the Lyerly lab simultaneously harvested 
tumor cells, splenocytes and hepatocytes from SCID mice bearing MDA-MB-468 tumors 
over the course of 72 hours and analyzed the viable cells by flow cytometry for the 
presence of HS-27. Figure 27a shows specific uptake of the probe by tumor cells, while 
splenocytes and hepatocytes did not. To test whether the probes were binding to Hsp90 
in vivo, or just accumulating in the tumors because of a blood pooling effect, excised 
tumor lysates were fractionated chromatographically. As shown in Figure 27b a single 
major peak of fluorescence was observed that contained Hsp90.  
Pharmacokinetic studies over 96 hours by optical spectroscopy performed by the 
Ramanujam lab more elegantly confirmed selective uptake of the tethered inhibitors. In 
this in vivo approach, a spectral pen was placed either at the tumor site or an adjacent 
skin patch, and the fluorescence spectrum measured from 500-620 nm. Figure 28 shows 
the signature spectrum of fluorescein at the tumor site and not at the adjacent skin sites 
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over a period of 6-24 hours post injection. Spectra were corrected for the effects of 
scattering and absorption from the tissue.  
 
Figure 28: Optical scanning for fluorescence in xenograft mice injected with 
HS-27 
To ensure that the in vivo probe accumulation within the tumor was ligand-
dependent, a control compound HS-105 was synthesized. HS-105 consists of the 
fluorophore and tether, minus the ligand. In affinity chromatography studies against 
Hsp90 bound to immobilized ATP, HS-105,  showed no affinity for the protein, and 
therefore any tumor retention would be non-specific (Figure 29a). In Figure 29b, HS-27- 
and HS-105-injected SCID mice were compared in tissues and xenografts. Excised 
tissues were measured for average radiant efficiency after 24 hours post injection. 
Tumors show retention of HS-27 whereas the lungs display a slight retention of HS-105.  
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Figure 29: HS-27 shows tumor specificity and the compound without ligand, 
HS-105, does not 
Using IVIS kinetic imaging, HS-27 was detected through the skin in live animals 
at one hour, whereas HS-105 was below detection (Figure 30). In more detailed 
necropsies, by 24 hours we found no trace of HS-105 by fluorescence whereas HS-27 was 
still present within the tumor (Figure 30).  
 
Figure 30: HS-27 retention in the tumor is dependent on the Hsp90 ligand 
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Next we sought to quantify the amount of HS-27 accumulation in the tumor by 
comparing the average radiant efficiency in the tumor to a standard curve of HS-27 
concentrations measured by the IVIS kinetic imager. We calculated that in a cohort of 5 
mice, the mean accumulation of HS-27 was 6.5 µM ±2.6 (SEM) at 24 hours. To test the 
utility of fluor-tethered Hsp90 inhibitors as potential means of non-invasive early tumor 
detection, the Lyerly lab designed an assay to test the sensitivity of the nIR version, HS-
70, in mice. MDA-MB-468 cells were treated ex vivo with HS-70 or control (untreated). A 
fixed number of cells were injected in an equal volume to the right flank of SCID mice. 
We found that HS-70 could be detected at as little as 100,000 cells (Figure 31).   
Figure 31: Ex vivo labeling of MDA-MB-468 cells with HS-70 and in vivo 
detection 
Current imaging approaches by MRI or PET/CT are estimated to reliably detect tumor 
masses at 1 cm3 with an estimated cell mass of ~10 million cells144,145. By these criteria, 
100,000 cells would suggest that nIR probes could theoretically detect masses as low as 
0.01 cm3. 
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Based upon our findings with the nIR probes, an obvious application for early 
malignancy detection would be surface tumors in which upregulation of Hsp90 has been 
indicated, such as head and neck, colorectal, bladder and melanoma139,146. Because nIR 
probes are limited to 3-4 cm in tissue depth, to enable whole body imaging we 
investigated an alternative approach using tethered Hsp90 inhibitors capable of carrying 
the radioisotope 125I ([125I]HS-111). Picomolar amounts of [125I]HS-111were added to 
either MCF7, BT474 or Huh7 cells and as observed with the fluor versions, the breast 
cancer cells exhibited uptake above Huh7 cells (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Radiolabeled Hsp90 inhibitor, HS-111, recognizes cell lines with 
ectopic Hsp90 
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Uptake of [125I]HS-111into MCF7 and Huh7 cells was then characterized after 
chromatographic fractionation and the probe was detected by its radioactivity. As 
observed with the fluor-tethered versions, in MCF7 cells, the majority of the 
radioactivity migrated as a single peak, in stark contrast to Huh7 cells which showed no 
peak recovery (Figure 32a). Importantly, the signal in MCF7 cells was effectively 
competed by the free ligand, HS-10 (Figure 32b). As with the fluor versions, β-escin 
permeabilization of Huh7 cells permitted the labeling of Hsp90 with [125I]HS-111in a 
competitive manner (Figure 32c,d).  
Importantly, HS-111 behaves similarly to the fluor-tethered versions in terms of 
its selectivity towards the breast cancer cell lines and entry to these cells also clearly 
requires active internalization through binding to ectopic Hsp90. Interestingly, HS-111 is 
more potent than the fluor versions in Her2 knock down assays suggesting faster 
kinetics of internalization and performed most closely to HS-10, the parent untethered 
compound. This is likely due to the differences in added steric bulk of the attached 
imaging moieties. HS-111 consists of a benzalamide moiety of 121.1 Da, whereas HS-27 
carries a bulky fluorescein moiety of 389.0 Da. Similarly, a lower rate of entry was 
observed with HS-96, a biotin-tethered Hsp90 inhibitor, which is considered to not 
passively diffuse across cell membranes (Figure 33). 
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Figure 33: Her2 degradation as a predictor of Hsp90 inhibitor internalization 
These data strongly suggest that one can readily manipulate the entry rate of 
tethered inhibitors into cells expressing ectopic Hsp90 by changing the properties of the 
tethered imaging moiety. The finding that tethered inhibitors with structurally diverse 
imaging prosthetic groups only enter cells expressing ectopic Hsp90, and at variable 
rates, discredits the possibility that the entry of the tested probes occurs only through 
simple diffusion.   
3.5 Conclusions 
Our data have shown that an important frontline cancer target, Hsp90, can be 
exploited through its role in the oncogenic process as a diagnostic marker for real-time 
imaging of metastatic status. This observation represents somewhat of a paradigm shift 
in the way we currently view cutting edge therapeutic targets such as Hsp90, and the 
concept could be extended to other therapeutic targets. Tethered Hsp90 inhibitors as 
imaging agents potentially add an element of diagnostic detail that cannot be garnered 
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from expression analysis or deep sequencing techniques. Specifically for Hsp90, these 
techniques do not measure the activation state of the protein or its localization, two 
important parameters linked to disease progression in breast cancer46,97. The urgency to 
exploit this approach is made more relevant by the recent landmark studies of Gerlinger 
et al. who demonstrated the degree to which tumors exhibit phenotypic heterogeneity, 
even within the same tumor114. Because expression analysis and deep sequencing only 
represent a fraction of a tumor’s global heterogeneous expression pattern at a single time 
point, these findings signal the limited utility of these approaches to stratify and 
diagnose tumors. However, because tumor growth requires the continued activation of 
signal pathways, then perhaps the development of fluor-tethered and other imaging 
inhibitors targeting proteins like Hsp90, or constitutively activated oncogenes like Her2, 
can offer a new alternative strategy to more accurately stratify disease progression 
through real-time, non-invasive imaging.   
If expression of ectopic Hsp90 signifies metastatic behavior in vivo, the fluor- or 
125I-carrying-tethered Hsp90 inhibitors could be used in conjunction with current biopsy 
practice to diagnose aggressive tumors. This would simply involve histological 
examination to determine probe uptake following microdose administration prior to the 
biopsy procedure. Moreover, non-invasive whole body PET imaging could be employed 
using 124I-containing tethered versions. The PET based approach is attractive because 
one could simultaneously determine the fate and distribution of the tethered inhibitor in 
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all tissues and in real-time. If PET analysis of a 124I-carrying-version showed highly 
selective targeting to the tumor in any one individual, one could proceed to a 131I version 
(which emits cytotoxic β-particles) with the goal of achieving complete body-wide 
tumor ablation without unwanted damage in normal tissues. The known µM 
accumulations of Hsp90 inhibitors (5-20 µM) within tumors and established protocols 
for the treatment of thyroid cancers with 131I should help accelerate the development of 
such treatment strategies41.  
The importance of ectopically expressed Hsp90 to the metastatic process has 
been established in a variety of ways including using a functional proteomic screen96  
and a non-cell permeable form of geldanamycin (DMAG-N-oxide) and anti-Hsp90 
antibodies, both of which block cellular migration in metastatic tumor lines107,140,143,147,148. 
The observation that fluor-tethered versions are selectively internalized by binding to 
ectopically expressed Hsp90 has revealed new roles for the protein in vivo. Although the 
expression of surface Hsp90 appears to be connected to cell migration and metastasis, 
the molecular mechanism by which ectopic Hsp90 signals to the tumor cell to promote 
these events is not known. Both migration to the surface and reinternalization of Hsp90 
could involve low copy clients, which may provide a means of signaling that promotes 
cellular migration and metastasis. This conclusion is supported by anti-Hsp90 antibodies 
that blocked reinternalization of Hsp90 as reflected by inhibition of HS-27 uptake into 
MCF7 cells. Irrespective of ectopic Hsp90 roles in metastatic progression, the knowledge 
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that the protein is reinternalized could be exploited to improve the safety margins of 
existing Hsp90 therapeutics or selectively deliver chemotoxic payloads to tumor cells. 
Compared to other cancer therapeutics, Hsp90 inhibitors are generally well tolerated by 
humans although some dose limiting side effects have been observed such as night 
blindness44. 
To many, the fact that inhibition of Hsp90 can be used therapeutically at all may 
seem paradoxical. After all, Hsp90 is thought to represent 1-3% of the expressed protein 
in most cells. This paradox is made even more extraordinary in the light of biochemical 
studies shown herein, with the finding that extracts from normal tissues contain 
considerable levels of active Hsp90. Various explanations have been offered in the past 
concerning the extraordinary selectivity of various Hsp90 inhibitors for tumor cells, 
including the idea that tumor cells express an oncogenically activated form of Hsp90 
with a higher affinity for Hsp90 inhibitors45. Our results suggest that the expression of 
ectopic Hsp90 may play a substantial role in the entry of Hsp90 inhibitors in general. 
This finding also suggests that in addition to tumor imaging, it may be possible to 
extend the therapeutic window of Hsp90 inhibitors by developing a range of molecules 
that do not passively diffuse across the plasma membrane, but can only enter cells 
expressing ectopic Hsp90.
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4. Hsp90 affinity and selectivity 
While most of the applications of Hsp90 tethered inhibitors appear to have 
promising clinical applications, conjugating Hsp90 inhibitors to sepharose beads has 
allowed us to uncover some fundamental Hsp90 biology, especially as it pertains to 
cancer. As stated in the introduction, we hypothesize that the three main differences in 
Hsp90 between cancer cells and normal tissues are (1) the induction, (2) the ectopic 
expression of Hsp90 on the cell membrane, (3) the activity or affinity of Hsp90 for ATP 
and its mimetics. For the remainder of this dissertation, I will focus on the activity and 
affinity of Hsp90 in cancer. Unlike others that use recombinant proteins, we have shown 
that native Hsp90 and Grp94 can be isolated and examined biochemically for activity 
and affinity. Additionally, using the unique tools of fluor-tethered Hsp90 inhibitors and 
Hsp90 affinity resins, we can test and refute previous claims about the differences of 
affinity found in normal tissue compared to tumors. We observed that one of the major 
differences is the conformation of Hsp90 in cancer cells. In cancer cells, there is a pool of 
Hsp90 that does not bind Hsp90 affinity resins and exhibits lower melting temperature 
despite being full length.   
4.1 Resin synthesis and evaluation 
A challenge in developing an affinity resin lies in choosing an appropriate ligand 
and devising chemistry that allows linker attachment without disrupting binding 
affinity. A structural analog of HS-10 in complex with the N-terminal domain of human 
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Hsp90 revealed the parts of the molecule which are solvent exposed and suggested a 
variety of substitutions likely to be tolerated at site number 1 ( 
Figure 34a,b)40. Further analyses suggested that replacing the trimethoxyphenyl 
group with a linker on a 3-methylpyrazole analog would provide a good balance of 
potency and ease of synthesis. Therefore, a fluoro-compound was initially synthesized. 
This intermediate provided a reactive center for the attachment of linkers and allowed 
for facile synthesis of a potent inhibitor, HS-10, for competition studies40.  
 
Figure 34: Hsp90 inhibitor in ATP binding pocket of Hsp90 
Affinity resins were prepared by reaction of the inhibitor–linker construct with 
activated affinity media, CNBr-activated Sepharose™ 4B according to the 
manufacturer’s instructions. Ligand was added at 1–10 µM/gram of resin in minimal 
methanol. Dr. Phil Hughes tried a commonly used linker that has the more hydrophobic 
n-decane linker to prepared affinity resin A and we analyzed its ability to selectively 
capture Hsp90 from pig mammary gland extract, a tissue shown to be high in ATP 
binding proteins including native forms of Hsp90, Grp94 and TRAP1 (Figure 35).  
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Figure 35: Purinome elution from ATP resin using 1 µM ATP 
The resin was incubated in the protein solution then washed with a high salt 
buffer. The bound proteins were removed via an SDS boil procedure, separated by SDS–
PAGE electrophoresis, located by silver staining and identified using mass spectrometry 
sequencing149. A large number of proteins, including Hsp90, were retained. Resin A 
proved capable of capturing Hsp90 and additional proteins, particularly in the 
competition experiments with HS-10 (Figure 36, lane A). This may be the result of 
enhanced and nonspecific hydrophobic interactions of proteins with the linker. We next 
examined affinity resin B using the short PEG-like 8 atom linker-construct. While the 
lane minus HS-10 appeared to have less non-specific binding, (Figure 36, lane B); 
however, the initial hypothesis that proteins other than Hsp90 might be clients was 
negated when a competition experiment, performed by pre-incubating the protein 
solution with HS-10 showed clean exclusion of Hsp90, but not the other proteins (Figure 
36, lane B). 
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Figure 36: Hsp90 affinity resins and competition 
We investigated another intermediate length PEG-like 13 atom linker and 
prepared affinity resin C. Although it was more selective than resins A and B, some 
nonspecific binding was observed (Figure 36, lane C). We next examined longer, more 
hydrophilic linkers that allowed the ligand to extend farther away from the Sepharose 
surface (Figure 37). Affinity resin D was prepared using the polyethylene glycol (PEG)-
like 19-atom linker-construct. The capture experiment was repeated and an intense band 
of Hsp90 was eluted with SDS (Figure 36, lane D). Importantly, competing with HS-10 
A
 
B
 
C
 
D
 
E
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showed complete blocking of Hsp90 binding as well as several N-terminal fragments. 
MS analysis demonstrated that all of the recovered proteins were Hsp90 or proteolytic 
fragments of the protein, suggesting that resin D is selective for Hsp90 over Grp94 and 
TRAP1. As mentioned previously (Figure 35), the pig mammary gland tissue contained 
adequate levels of Grp94 and TRAP1 to be detected by MS when eluted from an ATP 
resin with 1 µM ATP. All further experiments were therefore conducted with resin D, 
also referred to as HS-23 sepharose resin. 
 
 
 
 
Figure 37: Hsp90 affinity resins with different linkers modeled with 
homodimers of Hsp90 
4.2 Cleavable linker 
An important goal of our studies was to derive a probe that could be used to 
convincingly isolate Hsp90 under mild physiological conditions in association with 
potentially weakly associated client proteins. Although we can block Hsp90 recovery on 
our resins by competing with HS-10 or other Hsp90 inhibitors (e.g., geldanamycin or 
PU-H71)150,151, we were unable to elute Hsp90 bound to the affinity media without 
denaturing the protein. A linker that could be broken under non-denaturing conditions 
was needed. Recently, Verhelst et al reintroduced an azo-linker, which can be cleaved 
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under mild non-denaturing conditions with sodium dithionite solution152,153. This linker 
was synthesized using the published procedure and coupled to our ligand-construct, 
and through a two-step synthesis affinity resin E was derived. Following exposure to 
pig mammary gland extract and treatment of the resin with 25 mM sodium 
dithionite/100 mM Phosphate buffer pH 7.4, the eluted proteins were identified by MS 
as described earlier. The retained protein profile (Figure 36, lane E) is essentially 
identical to resin D, except that the proteins are recovered under non-denaturing 
conditions.  
4.3 Nonspecific binding 
One observation in these experiments (Figure 36) is that the binding of Hsp90 to 
each of the resins seems to lower the level of non- specific binding, effectively protecting 
the resin. With each of the affinity resins (A–E), addition of HS-10 to the protein mixture 
completely blocked Hsp90 binding allowing recovery of other proteins, especially 
abundant proteins such as fatty acid synthase (240 kDa). Although binding of these 
proteins is clearly not Hsp90 related their recovery illustrates the challenges of using 
affinity media to study interactions with Hsp90. Even with a highly optimized ligand, 
our results illustrate the extent to which affinity based strategies in defining Hsp90 
clients can lead to incorrect conclusions. To define physiologically relevant associations 
with Hsp90, it is necessary to demonstrate competitive binding with a free ligand. 
Competition experiments should be carried out using a selective inhibitor of Hsp90 in 
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the cell/tissue extract prior to exposure to the affinity resin. Under these conditions, 
recovery of Hsp90 and any associated proteins should be selectively blocked. Proteins 
recovered in the presence of the free ligand are likely to be non-specific. 
4.4 Selectivity evaluation 
The finding that neither Grp94 nor TRAP1 was recovered by the HS-23 sepharose 
resin suggests that HS-23 is highly selective for Hsp90. To explore this selectivity in a 
somewhat reverse fashion, we tested the elution of pig mammary gland proteins from a 
gamma phosphate linked ATP Sepharose resin with HS-10, HS-23 and compared them 
to other known potent Hsp90 inhibitors: 17-AAG,  PU-H71, and SNX2112 (Figure 
38)40,151,154.  
 
Figure 38: Elution of Hsp90 and Grp94 from the ATP-sepharose resin 
This ATP resin has been used in our lab for several years to study purine-binding 
proteins and to discover novel Hsp90 inhibitors41,155.  It can be used to test ligand binding 
selectivity against all other purine utilizing enzymes expressed in cells. The ATP resin 
HS-10 
SNX-2112 
PU-H71 
17-DMAG 
HS-23 
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was charged with the pig mammary gland extract and aliquots were distributed into 
individual wells. Proteins eluted from the wells with increasing amounts of the 
indicated compound were analyzed as described earlier (Figure 39).  
 
Figure 39: Elution of pig mammary gland protein from ATP-sepharose resin 
with SNX-2112, PU-H71 or HS-23 
Compound PU-H71 demonstrates strong potency towards both Hsp90 and 
Grp94, whereas SNX2112 shows weaker affinity for Grp94 and HS-23 shows essentially 
no elution of Grp94. Examination of the crystal structures of Hsp90 and Grp94 with 
various ligands provided no obvious clue as to why HS-23 would display a greater 
binding selectivity for Hsp90 over Grp94 compared to the other known Hsp90 
inhibitors. It may be that the hydration of the PEG linker attached to HS-23 gives rise to 
a relatively larger, more sterically demanding structure, which precludes binding to 
Grp94. 
HS-23 
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4.5. Grp94 purification 
It was possible to use this differential selectivity to purify Grp94. Pig mammary 
gland extract was passed through cleavable HS-23 sepharose resin, efficiently removing 
Hsp90, directly onto the ATP-resin. Elution of the ATP resin with PU-H71 gave clean 
Grp94 when analyzed by SDS–PAGE, silver staining and mass spectrometry (Figure 40). 
 
Figure 40: Purification of Grp94 from Hsp90 
In (A) the pig mammary gland purinome was captured on ATP resin then eluted 
with PU-H71 releasing Grp94 and Hsp90 as expected. In (B) pig mammary gland extract 
was first passed through cleavable HS-23 sepharose resin and the flow through was then 
applied to ATP sepharose resin. The ATP sepharose resin was then eluted with 10 µM 
PU-H71 to yield pure Grp94. In (C) cleavable HS-23 sepharose resin was eluted with 30 
mM sodium dithionite to yield Hsp90. 
4.6 Proteomic studies 
To test cleavable HS-23 sepharose resin as a proteomics tool we surveyed mouse 
organs to determine both Hsp90 expression levels between tissues and to define novel 
client proteins. Physiological conditions were used to preserve weak binding 
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interactions with Hsp90. To demonstrate specificity, extracts were mixed with resin 
cleavable HS-23 sepharose resin ± HS-10. As seen in Figure 41A, each mouse tissue 
yielded a prominent protein at 90 kDa of varying abundance as well as a distinct pattern 
of proteins of varying molecular weight. In most instances, inclusion of HS-10 in the 
extract blocked recovery of the 90 kDa protein as well as the additional proteins (Figure 
41B). As expected, the 90 kDa protein was identified by mass spectrometry as Hsp90 (α 
and β isoforms). Surprisingly, many of the other proteins in the gel were either N-
terminal fragments of Hsp90 or dimers of the holoenzyme (Figure 41).  
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Figure 41: Proteomic survey of mouse tissues with the cleavable HS-23 
sepharose resin1 
Some proteins do appear to be potential clients of Hsp90 and show tissue specific 
associations including delta(3,5)-delta(2,4)-dienoyl-CoA isomerase, NADPH-dependent 
retinol dehydrogenase/reductase, acetyl-CoA acyltransferase and glycogen debranching 
enzyme. Two proteins, epoxide hydroxylase and glutaryl-CoA dehydrogenase, are 
tentatively identified as novel clients, since recovery of these proteins was not 
                                                   
1 Tissue extracts were prepared from the indicated tissues and applied to a fixed volume of resin E (100 µl) 
in the absence (A) and presence (B) of HS-10 (100 µM). Following washes at physiological ionic strength the 
bound proteins were eluted with 30 mM dithionite and characterized by SDS–PAGE (4–15% acrylamide), 
silver staining and mass spectrometry. Key: 1–22. Full length Hsp90a/b or N terminal fragments of 
Hsp90a/b; 23. Epoxide hydroxylase; 24.Glutaryl-CoA dehydrogenase; 25. and 26. Hsp90a/b; 27. Hsp70; 28. 
Epoxide hydroxylase; 29. Delta(3,5)-delta(2,4)-dienoyl-CoA isomerase; 30. 3,2-trans-Enoyl-CoA 
isomerase/NADPH-dependent retinol reductase; 31 and 32. Hsp90a/b; 33. Hsp70; 34. Hsp90a/b; 35. 
Glycogen debranching enzyme; 36 and 37. Hsp90a/b; 38. Epoxide hydroxylase; 39. 3-Ketoacyl-CoA 
thiolase/3-ketoacyl-CoA thiolase; 40–42. Hsp90a/b; 43. Hsp70; 44. Epoxide hydroxylase/liver 
carboxylesterase 31; 45–47 Hsp90a/b; 48. epoxide hydroxylase; 49–51. Hsp90a/b; 52. Albumin; 53. Hsp90a/b; 
55. Albumin; 56. CAZ-associated structural protein 1/Ankrd11 protein; 56. Hsp90a/b; 57. Albumin; 58. 
Epoxide hydroxylase; 59. Glutaryl-CoA dehydrogenase; 60. Hsp90a/b. Combined consisted of a mixture of 
striated muscle, liver, testis and adipose tissue. The lane w/o dithionite was eluted with SDS. This gel is a 
representative example of using resin E against tissue extracts. 
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completely blocked by HS-10. Their recovery may be explained by the presence of 
residual Hsp90 co-elution. Figure 41B also shows, as observed earlier, a few proteins 
were still non-specifically recovered from some tissues, even in the presence of HS-10, 
including albumin, CAZ-associated structural protein 1 and Ankrd11 protein. Their 
recovery underscores the necessity of including a competition control with the free 
ligand to directly demonstrate Hsp90 dependence of the co-isolation. As a positive 
control, we confirmed that we could use cleavable HS-23 sepharose resin to find Her2; a 
known client of Hsp90. Extract from the breast cancer cell line BT474 was added to the 
resin ± HS-10. Cleavage of the linker with dithionite and analysis by SDS–PAGE and 
silver staining showed only Hsp90. However, Western blot analysis clearly showed the 
presence of Her2 (Figure 42). Neither Hsp90 nor Her2 were seen in the sample competed 
with HS-10. 
 
Figure 42: Proteomic analysis for Her2/Hsp90 interactions using the cleavable 
HS-23 sepharose resin 
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4.7 Conclusions 
We reported the development of a novel affinity probe, cleavable HS-23 
sepharose resin, for the selective recovery of Hsp90 in native complex with its 
physiologically relevant client proteins. Our ligand is the first reported affinity reagent 
that only binds Hsp90 and shows no affinity for Grp94 and TRAP1 at the limits of silver 
staining and mass spectrometry analysis. Therefore, cleavable HS-23 sepharose resin 
enables the study of native client proteins selective for Hsp90 independent of other 
chaperones. The development of cleavable HS-23 sepharose illustrates the complexities 
of utilizing affinity approaches to study native protein–protein interactions. Clearly, 
linker choice is critical to avoid artifacts. Study of Hsp90 is particularly challenging 
because interactions with its clients may be weak and readily disrupted under stringent, 
non-physiological conditions. Before assigning a particular protein as a client or co-
chaperone of Hsp90, it is essential to also perform a co-isolation experiment with the 
appropriate competition control. Any proteins recovered under competing conditions 
are probably artifacts and unlikely to be a client or co-chaperone of Hsp90. In proteomic 
studies of mouse tissues using cleavable HS-23 sepharose, Hsp90 was recovered either 
alone or in association with novel client proteins. Recovery of the putative clients was 
authenticated by the competition experiments with HS-10. Interestingly, the majority of 
the recovered clients are associated with the metabolism of various lipids namely 
delta(3,5)-delta(2,4)-dienoyl-CoA isomerase, acetyl-CoA acyltransferase, NADPH-
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dependent retinol reductase and epoxide hydroxylase 2. Delta(3,5)-delta(2,4)-dienoyl-
CoA isomerase and acetyl-CoA acyltransferase are peroximal enzymes participating in 
β-oxidation of long chain fatty acids. Delta(3,5)-delta(2,4)-dienoyl-CoA isomerase 
isomerizes 3-trans,5-cis-dienoyl-CoA to 2-trans,4-trans-dienoyl-CoA functioning as an 
auxiliary step of the fatty acid β-oxidation pathway, enabling the metabolism of 
unsaturated fatty acids in mammals. NADPH-dependent retinol reductase (RDH12) has 
activity toward 9-cis and all-transretinol and is involved in the metabolism of short-
chain aldehydes. The enzyme forms 11-cis-retinal from 11-cis-retinol during 
regeneration of the cone visual pigments. Mutations in the RDH12 are associated with 
retinitis pigmentosa type 53156,157. Retinitis pigmentosa is characterized by retinal 
pigment deposits as well as loss of rod photoreceptor cells with some secondary cone 
photoreceptor loss. The condition is typified by night vision blindness and reduced 
peripheral visual field. If RDH12 is a client for Hsp90, loss of expression of the protein in 
the eye could explain some of the idiosyncratic visual side effects anecdotally reported 
in some patients treated with a variety of Hsp90 inhibitors in clinical trials44. This would 
require that these drugs cross the blood–brain barrier since the retina is contiguous with 
the central nervous system. Epoxide hydroxylase 2 and its immediate family members 
have roles in the metabolism of arachidonic and linoleic acid epoxides, as well as, 
xenobiotics158. The finding that epoxide hydroxylase 2 is a client of Hsp90 could explain 
 95 
some of the anti-inflammatory effects of Hsp90 inhibitors in addition to their indications 
in cancer159,160. 
The mouse study was used primarily to demonstrate the use of the affinity resin 
for initial identification of potential client proteins. Further studies are needed to 
confirm that these proteins are true clients of Hsp90. As shown with the breast cancer 
cell line, actual client proteins may be present below the detection limits of silver 
staining or mass spectrometry detection but still be detectable by western blot analysis. 
A final observation relates to the impact of the linker choice on the performance of an 
affinity resin. There is a radical difference in the amount of nonspecific binding between 
using the n-decane linker (resin A) and PEG-6 linker (resin D). We were initially 
disappointed with the number of clients identified with our affinity media, although we 
now believe the approach of using a ‘clean’ cleavable linker along with a quenching 
agent gives rise to fewer experimental artifacts. It may be worthwhile to reexamine other 
affinity experiments where hydrophobic linkers are used, beyond the field of chaperone 
proteins. Judicious linker replacement may show some affinity experimental conclusions 
to be premature and may yet yield positive results in other previously failed 
experiments. 
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5. Hsp90 isoform specific inhibitors 
Cancer progression is characterized by rapidly proliferating cancer cells that 
require increased protein synthesis to contribute to  other hallmark phenotypes of 
cancer2. Heat shock proteins are well conserved and abundant proteins that buffer the 
noxious effects of the often harsh tumor microenvironment by chaperoning unstable or 
misfolded proteins49. The over expression of Hsp90 and its correlation to patient 
outcome is well documented in a number of cancers57-63. Thus, Hsp90 inhibitors have 
been the recent subject of intense pharmaceutical research in cancer52,53,138.  All Hsp90 
inhibitors that have reached clinical trials bind to the Hsp90 N-terminal ATP-binding 
pocket and demonstrate pan-Hsp90 inhibition51,138. Toxicities and off target effects 
resulting from Hsp90 inhibition could be attributed in part to the pan-inhibition of its 
family members Hsp90α and β, Grp94, and TRAP1. Therefore, the design of Hsp90 
isoform-specific inhibitors may provide valuable pharmacological tools to dissect the 
roles of each isoform and may lead to more clinically useful inhibitors. 
Cytosolic Hsp90 is the most studied of the isoforms and most experimentation 
using pan-Hsp90 inhibitors attributes their effects to the inhibition of Hsp90α and β. 
Cytosolic Hsp90α and β play pivotal roles in cell signaling by chaperoning steroid 
hormone receptors and proto-oncogenic kinases. The effects are pleiotropic and seem to 
be growing because of the expanding interactome and ubiquitous expression reported in 
the literature66. Despite these cautionary signs, many inhibitors targeting Hsp90 have 
 97 
successfully advanced through clinical trials, demonstrating patient responsiveness with 
higher than expected maximum tolerated doses. The interaction between Hsp90α and β 
and its clients is thought to be very transient, making it difficult to qualify and quantify 
any binding25. Recently, studies have revealed that inhibitors bound to Hsp90 abrogate 
binding of most of the putative clients and co-chaperone proteins47.  While Hsp90α and 
β are major contributors to the progression of tumorigenesis, Grp94 and TRAP1 make 
distinct contributions to cancer progression and the development of resistance to chemo 
and targeted cancer therapies133.  
Grp94 is an Hsp90-like protein that facilitates proper folding of denatured 
proteins in the lumen of the ER as well as their transport to other organelles including 
the plasma membrane161,162. Unlike Hsp90’s clients, Grp94’s client proteins exhibit 
commonalities that make them more predictable interactors. Grp94 recognizes the 
immunoglobulin domain fold, which is found in many secretory proteins. In addition, 
every known client of Grp94 contains disulfide bonds, suggesting another way by which 
Grp94 is able to recognize substrates. A list of these clients is provided in a recent 
review163. While the interactions appear to be more predictable, there are still unknowns 
in the field of immunology as to how Grp94 binds and presents a wide array of peptides 
for T cell antigen recognition164. Grp94 is often overexpressed in cancers, which also 
implies it can be used as a candidate biomarker for monitoring tumor progression165,166. 
In cancer, Grp94 is needed to chaperone proteins in the ER that are under the stresses of 
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acidosis, glucose deprivation, and hypoxia, otherwise an unfolded protein response 
would be triggered through the PERK, XBP-1, and ATF6 signaling pathways that could 
result in apoptosis167. Grp94 has also been implicated as playing a cytoprotective role in 
etopside-induced apoptosis by directly interacting with calpain168. Inhibitors against 
Grp94 inhibitors would sensitize tumors to other chemotherapies, shifting the balance 
from survival to controlled cell death. However these tools are underdeveloped with 
very few promising leads.  
TRAP1 is the mitochondrial isoform of the Hsp90 family that was first identified 
by its interaction with the intracellular domain of the type I TNF receptor169. Subsequent 
sequence analysis demonstrated that TRAP1 is indeed Hsp7532. While its primary 
cellular residence is the mitochondria, it also localizes to the cytoplasm, ER and 
nucleus170-172. The interactome for TRAP1 is significantly less than Hsp90; however, it 
does chaperone an important mitochondrial protein, Sorcin, and even the nuclear 
protein, Rb, that protect cells against apoptosis and oxidative stress170,173-177. Through 
these functions, TRAP1 has been proposed to facilitate chemoresistance by buffering the 
effects of drug-induced apoptosis in cancer cells177-179.  
Several efforts are being made to design isoform-specific inhibitors and some 
endeavors are focusing on the differential expression of these isoforms from each other 
and the ectopic expression found in tumor cells110,133,180-182. One recent report by Patel et 
al, hypothesized that the conformational differences between Hsp90 and Grp94 could be 
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exploited by a ligand-induced selectivity for the Grp94 ATP-binding pocket. Based on 
their affinity and selectivity, we synthesized their most potent and selective Grp94 
inhibitor, PU-H39180. Our goals were to make affinity chromatography resins to 
proteomically mine for bona fide clients and co-chaperones and to isolate Grp94 for 
more elegant biochemical assays for comparison to Hsp90. However, PU-H39 did not 
show potency for Grp94 in our native protein elution assays. Using a combination of 
affinity chromatography resins, we isolated native Grp94 and Hsp90 and performed 
thermal stability assays, which confirmed the selectivity of our tethered Hsp90 inhibitors 
and lack of potency of PU-H39. Tethered Hsp90 inhibitors, such as HS-23, further 
showed in vivo activity against Her2 and upregulation of Hsp70, whereas the unfolded 
protein response was only detected in the pan-Hsp90 inhibitors.  
5.1 Selectivity of Hsp90 inhibitors in a competitive elution assay 
Rather than working with exogenously overexpressed proteins, we looked at 
endogenous heat shock proteins from a lactating pig mammary gland. This tissue has 
been shown to express all isoforms of Hsp9047. Using a dose titration of inhibitors, we 
eluted protein from a charged ATP-sepharose resin that had been loaded with 
homogenized pig mammary tissue. We compared known pan-Hsp90 inhibitors, HS-10 
and PU-H7147,151, to the recently reported Grp94 selective inhibitor, PU-H39180. At the 
level of detection of silver staining, we found predictable patterns of elution of Hsp90 
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and Grp94 for the pan-Hsp90 inhibitors. However, PU-H39 failed to elute any purine 
binding proteins from the ATP-sepharose resin (Figure 43).  
 
Figure 43: Hsp90 and Grp94 elution from the ATP sepharose resin 
 
Interestingly the lower molecular weight bands (black arrows) were identified as 
truncated Hsp90 and Grp94. The truncations occurred similarly in the C-terminal end of 
both proteins (Figure 44).   
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Figure 44: Amino acid MS coverage of Hsp90 and Grp94 C-terminal 
truncations 
To test the elution at a more sensitive level, we probed the eluate for Hsp90, 
Grp94 and Trap1 by immunoblotting.  Using this analysis, we examined the specificity 
of HS-10, HS-23, and PU-H39 and we observed that HS-10 exhibits the highest affinity 
for the different isoforms with HS-23 showing some selectivity and PU-H39 showing no 
selectivity for any of the Hsp90 isoforms (Figure 45).  
 
Figure 45: Grp94, TRAP1 and Hsp90 elution from ATP sepharose resin 
 102 
To maximize the opportunity of PU-H39 binding to Grp94, we pretreated tissue 
lysates with DMSO, 10 µM PU-H71, or 10 µM PU-H39 before loading on the ATP-
sepharose resin. All samples were eluted with a dose titration of PU-H71. As expected 
DMSO did not block the binding of Hsp90 and Grp94 and they were eluted 
demonstrating the typical elution pattern (Figure 46). Contrastingly, to DMSO, the 
pretreatment of PU-H71 competitively blocked the binding of Hsp90 and Grp94 to the 
ATP-sepharose and thus no protein was captured with the elution of PU-H71 (Figure 
46). Interestingly, both Hsp90 and Grp94 were eluted (similar to DMSO) when 
pretreated with PU-H39 and eluted with PU-H71 (Figure 46).  
 
Figure 46: Hsp90 and Grp94 elution with PU-H71 titration with pretreatment 
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If PU-H39 is a bona fide selective inhibitor of Grp94, one would predict that Grp94 
would be competitively blocked and only Hsp90 would be eluted using PU-H71. This 
evidence contradicts the earlier reports of PU-H39’s nanomolar potency and 
selectivity180.  
5.2 Native Hsp90 and Grp94 purification 
To perform more elegant biochemical experiments on the interaction of these 
inhibitors with Hsp90 and Grp94, we needed to isolate native protein. To achieve this 
goal, we devised a sequence of purifications and elutions using an Hsp90-selective 
affinity resin, the ATP-sepharose resin, and a pan-Hsp90 inhibitor. The schematic is 
diagramed in Figure 47. First, we added homogenized tissue to the Hsp90 selective resin 
Figure 47a) to deplete both Hsp90α and β. These proteins were eluted off the sepharose 
resin by reductively cleaving the linker using 25 mM sodium dithionite (Figure 47II). 
The ligand was dialyzed away using decreasing amounts of ATP until Hsp90 was 
unbound from the ligand and ATP. The flow through from the Hsp90-selective affinity 
resin (Figure 47I) was collected and loaded onto an ATP-sepharose resin (Figure 47b). 
After thoroughly washing the ATP-sepharose resin, proteins were eluted using a pan-
Hsp90 inhibitor, HS-10. Because Hsp90 had been previously depleted, the only protein 
captured and identified by mass spectrometry was Grp94 (Figure 47III). 
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Figure 47: Schematic of native Hsp90 and Grp94 using affinity resin 
chromatography 
 
5.3 Thermal Stability of Hsp90 and Grp94 reveals selective 
Hsp90 inhibitors 
Once we confirmed that we had pure samples of Hsp90 and Grp94 by SDS-
PAGE gel electrophoresis and mass spectrometry (Figure 47), we analyzed the thermal 
stability of these proteins in the presence of the different Hsp90 inhibitors. ATP 
competitive inhibitors typically confer thermal stability to purine binding proteins, and 
this often equates with affinity of the molecule for its protein target183-185. Using purified 
Hsp90 and Grp94, we observed an increase in melting temperature (Tm) using pan-
Hsp90 inhibitors HS-10 and PU-H71 (Figure 48). However, the tethered Hsp90 
inhibitors, HS-23 and HS-32, demonstrated selectivity for Hsp90 (Figure 48a), and no 
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stability was conferred upon Grp94 (Figure 48b). This confirms the results of previous 
assays that adding a tether to HS-10 to form HS-23 bestows selectivity for Hsp90 
regardless of the chemical moiety on the distal end of the linker (Figure 49). These 
linkers and added chemical moieties come with a price as affinity is usually measured to 
be half as potent as the established pan-Hsp90 inhibitors in shifting the thermal stability. 
However, the affinity of these tethered Hsp90 inhibitors for Hsp90 is still in the 
submicromolar range. Next we examined the selectivity of PU-H39 under like 
conditions and thermal stability was not observed for Hsp90 or Grp94 (Figure 48c,d). 
We have therefore further demonstrated a lack of affinity and selectivity of PU-H39 for 
any of the native isoforms of Hsp90.  
 
Figure 48: Thermal stability of Hsp90 and Grp94 in the presence of pan and 
selective Hsp90 inhibitors 
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Figure 49: Thermal stability of Hsp90 in the presence of pan Hsp90 inhibitors 
and tethered Hsp90 inhibitors 
 
5.4 In vivo biological activity of Hsp90 selective inhibitors 
While some discrepancies exist between our findings and Patel et al, the 
biochemical affinity could be explained by the use of recombinant proteins and not 
native proteins. To evaluate the effects of these compounds in a biological context, we 
analyzed the classical client degradation of Her2 in BT474 cells and the well-
characterized upregulation of Hsp70, both of which are associated with Hsp90 
inhibition. After 12 hours of treatment with a dose titration, we found that pan-Hsp90 
inhibitors exhibited potent degradation of Her2 and upregulation of Hsp70 at an EC50 < 1 
µM (Figure 50a,b,e). Tethered Hsp90 inhibitors also demonstrated similar potency with 
the exception of HS-132, which contains a nIR fluorophore attached to the distal end of 
the linker, affecting its cellular bioavailability (Figure 50a,b,e). Intriguingly, the 60 µM 
EC50 correlates inversely with the fluorescent uptake measured intracellularly in the 
BT474 cells (Figure 50d). In contrast, no effects on Her2 and Hsp70 were observed upon 
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treatment with PU-H39 (Figure 50a,b,e). Additionally, none of the compounds exhibited 
deleterious effects on Hsp90 (Figure 50c,e). We also looked for an unfolded protein 
response as exhibited by an increase in Erdj3, a classical molecular marker of Grp94 
inhibition. After 12 hours of treatment, no response was detected in cells treated with 
PU-H39 at 3 orders of magnitude higher than the reported Kd (Figure 51a,c)180. There 
was, however, a modest increase in Grp94 expression across all treatments including 
PU-H39 (Figure 51b,c). The decreases in protein expression with higher treatments of 
HS-32, the bis-ferrocene conjugated Hsp90 inhibitor, can be attributed to the ferrocene 
molecules and not Hsp90 inhibition because HS-10 treatments at these doses and for 12 
hours did not exhibit deleterious effects on the cells (Figure 51d). Together these data 
demonstrate PU-H39’s lack of potency at the biochemical level and lack of biological 
activity at the cellular level. However, we have demonstrated that tethered Hsp90 
inhibitors can be used for biological and biochemical analyses of Hsp90.  In addition, the 
effects seen in these studies can be confidently attributed to the mechanism of action of 
Hsp90, albeit the complexity largely remains. We also have devised a method to purify 
native Hsp90 and Grp94 from tissue using Hsp90 selective affinity chromatography, 
ATP-sepharose chromatography and pan-Hsp90 inhibitors. This method could facilitate 
the discovery of other truly potent and selective inhibitors of Grp94 and Hsp90.  
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Figure 50: Biological activity of Hsp90 selective inhibitors 
e 
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Figure 51: Detection of the unfolded protein response in MDA-MB-468 cells 
 
5.5 Conclusions 
There are on-going attempts to tease apart the mechanisms of the four isoforms 
of Hsp90, how each isoform uniquely contributes to cancer, and more importantly how 
each can be selectively targeted in cancer and not in normal tissues. Small molecule 
inhibitors that distinguish the different Hsp90 isoforms will greatly advance our 
understanding of this important field. Unfortunately, PU-H39 demonstrates neither the 
potency nor the selectivity as previously reported180. A number of reasons could explain 
the discrepancies. First, in the previous report, the screening of inhibitors involved a 
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tagged recombinant version of Grp94. Not only was the protein tagged, but it 
represented less than half of the protein (aa 66-337). Second, although we chose PU-H39 
to synthesize and study based on the potency and selectivity reported, a number of PU 
analogues were reported and by chance, we selected a biologically inactive compound 
that does not bind native Grp94 in vitro. Lastly, the crystal structure remains enigmatic 
especially pertaining to the hinge in vicinity of the active site. We believe the 
crystallographic data to be artificial and using a truncated protein for this study further 
riddles this study with artifacts. In our own examination of the crystal structures of 
Hsp90 and Grp94 with various ligands, we saw no obvious clue as to why tethered 
Hsp90 inhibitors such as HS-23 would display a greater binding selectivity for Hsp90 
over Grp94 and TRAP1 compared to the other known Hsp90 inhibitors. It may be that 
the hydration of the PEG linker in HS-23 gives rise to a relatively larger, more sterically 
demanding structure, which precludes binding to Grp94. The study supports evidence 
that selectivity between Hsp90 isoforms can be achieved and that native protein studies 
demonstrate advantages over recombinant proteins and reduce the risk of committing a 
type I error.  
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6. Unfolded Hsp90 in cancer cells 
6.1 Introduction 
Hsp90 facilitates many of the molecular steps in a tumors progression from being 
benign to becoming malignant and invasive. In order to undergo cell behavior that is 
implicated in metastatic tumors, one must envision molecular changes at the cell 
membrane. Indeed, Hsp90 is found on the surface of tumors and not on the surface of 
normal tissue110. Extracellular Hsp90 has been shown to stimulate migration and 
invasion of cancer cells98. We have used this unique phenomenon to design large, polar 
Hsp90 inhibitors tethered to fluorophores to detect and study extracellular expression in 
cancer cells110. In addition to the extracellular differences in Hsp90, we highlight new 
findings that there are seminal differences between cancer and normal tissue in Hsp90’s 
stability found in these cells.  
6.2 Normal tissue HS-27 affinity compared to breast cancer cells 
In 2003, it was reported that Hsp90 exhibited a unique expression in cancer as a 
multimeric complex with other co-chaperones and that these complexes demonstrated 
higher affinity for inhibitors such as 17-AAG and higher ATPase activity45. We, however, 
have found that Hsp90 is devoid of its co-chaperones when retrieved using affinity 
ligand chromatography47. We have since tested the hypothesis that there are affinity 
differences between normal and tumor tissues. First, we optimized an assay using HS-27 
binding to protein extracts and fluorescent detection in a 96-well plate to determine the 
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affinities for different tissues. Unbound HS-27 was washed thoroughly in a 96-well 10K 
kDa filter plate followed by elution of the protein samples through a pinhole into a catch 
plate. Using purified Hsp90, we added 1.14 µM, 11.4 µM or 114 µM HS-27 to a range (0.1 
to 500 µg) of purified Hsp90 (Figure 52a). According to these results, we chose to focus 
more exclusively on the 10-100 µM range of HS-27, and then we performed competition 
experiments with HS-10 so as to demonstrate that any signal retained could be 
attributed to the binding of HS-27 to the protein. The competition experiments 
effectively reduced the signal (Figure 52b). Another important observation is that 
regardless of the increase in protein and the correlative increase in HS-27 retention as 
determined by fluorescence, the affinity remained constant (mean 340 nM, SEM ±38 nM) 
as determined by the apparent Kd equation1 using the EC50 of the curves (mean 68.5 µM, 
SEM ±7.7 µM) (Figure 52).  
 
                                                   
1 Apparent Kd  = EC50/[1 + (ATP concentration/Km)]186. Haystead, T.A. The purinome, a complex 
mix of drug and toxicity targets. Current topics in medicinal chemistry 6, 1117-1127 (2006). 
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Figure 52: Optimization for Hsp90 affinity assay using HS-27 
Based off these data, we determined that the optimal amount of Hsp90 per well 
is 50-100 µg. As Hsp90 is 2-3% of the total protein of a cell, we estimated that we would 
need about 2,000 µg of total protein in each well from the harvested mouse tissues and 
human breast cancer cells. We focused primarily on tissues that have exhibited high 
expression of Hsp90 in our past experiments, namely brain, kidney, liver, spleen and 
lung. Using this technique, we can measure both the relative abundance of Hsp90 and 
its affinity for Hsp90 inhibitors such as HS-27. We report that there is no disparity in 
affinity for Hsp90 and HS-27 between MDA-MB-468 breast cancer cells and the normal 
tissues harvested from mice (Figure 53).  
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Figure 53: HS-27 affinity is the similar between cancer cells and normal tissues 
 
 
6.3 The unfolded Hsp90 protein is unique to cancer cells 
We have previously published that there is a fraction of intracellular Hsp90 that 
does not bind to our small molecule affinity chromatography resin and this is congruent 
with the Chiosis lab at Sloan-Kettering46,110. In our attempts to isolate the flow through 
pool and perform proteomic comparisons between the drug-binding pool and non-drug-
binding pool, we came across an original observation that normal tissue from mice or 
pigs does not contain Hsp90 in the flow through after resin depletion. In other words, 
there is a population of Hsp90 that does not bind to affinity chromatography resins in 
cancer cells that is not found in normal tissues. We developed an in-plate assay for 
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analyzing many tissue sources in replicate and in parallel. To validate that a through-put 
assay could still discriminate between resin-bound Hsp90 and flow through Hsp90 after 
scaling down our samples, we looked at MDA-MB-468 and SKBr3 cells and observed the 
expected pattern of resin capture, followed by depletion and presence of Hsp90 in the 
flow through (Figure 54).  
 
Figure 54: Resin depleted Hsp90 detected in breast cancer cell lines 
However, when we assayed normal mouse tissues under the same conditions, 
we detected no Hsp90 in the flow through after the 3rd resin depletion pass (Figure 55).  
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Figure 55: Hsp90 resin depletion reveals no Hsp90 in flow through for normal 
tissues 
We found that cultured human breast cancer cells contained inactive Hsp90 and 
normal tissues from mice, such as eyes, brain, lung, liver, spleen and kidney did not.  To 
validate that the flow through was not an artifact of in vitro culturing or harvesting, we 
took three human breast cancer xenografts from mice and observed that these tumors 
also exhibited a pool of Hsp90 that would not bind the affinity resin (Figure 56).  
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Figure 56: Resin depleted Hsp90 detected in breast cancer xenografts 
6.4 Thermal stability reveals unfolded nature of resin depleted 
Hsp90 
At this point, we questioned what the differences between these two pools of 
Hsp90 were. It is noted that the flow through Hsp90 is found primarily in its full length 
form and the truncated forms that have been observed have been confirmed to be 
missing the C-terminal end, which is opposite of the N-terminal ATP binding domain. 
There are two hypotheses: (1) either the ATP-binding domain is misfolded and that does 
not permit binding or (2) there is something bound in the binding pocket that precludes 
the binding of inhibitors. A thermal stability assay helped differentiate between these 
two possibilities. An increased shift in the transition temperature would support that 
something is bound and stabilizing the protein whereas a decreased shift in the 
transition melt temperature would suggest a less stable conformation of the protein that 
distorts the ATP binding pocket. In order to isolate the flow through Hsp90 from the 
mouse 1 
mouse 2 
mouse 3 
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milieu of cell lysate proteins, we chromatographed inactive Hsp90 over a mono Q 
column. Wells were separated by gel electrophoresis and silver stained and suspected 
bands were analyzed by mass spectrometry and confirmed to be Hsp90. The 
corresponding wells were pooled and concentrated and thermofluor data was obtained. 
It was noted that the active pool of Hsp90 exhibited a transition melt temperature of 
50°C which was increased 9°C by the presence of the small molecule inhibitor HS-10. 
However, the inactive Hsp90 demonstrated a 9°C shift to the left that was not rescued in 
the presence of HS-10, which supports the unstable conformation hypothesis (Figure 57).  
 
Figure 57: Thermal stability assay for active and inactive Hsp90 
6.5 Conclusions 
This discovery of misfolded chaperones in cancer is a novel finding and parallels 
the molecular mechanisms associated with neurodegenerative diseases such as 
Alzheimer’s disease (AD). Indeed there are already several parallels between the 
aberrant signaling in cancer and in AD that incriminates Hsp90 chaperone function and 
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several research groups have proposed that patients with AD could benefit from Hsp90 
inhibitor therapy187. Cancer is a complex conglomeration of signaling events that 
promote cell survival, growth, division, migration and invasion2. Alzheimer’s disease is 
also very complicated demonstrating aberrant signaling cues from several 
hyperphosphorylated proteins. Neuronal cells promote survival in opposition to the 
accumulation of β-amyloid peptides and neurofibrillary tangles and the 
neuroinflammation of neighboring glial cells; however the upregulation of chaperones 
to buffer these cellular stresses most likely facilitates disease progression that leads to 
neuronal cell death188.  
Our novel finding that cancer has a pool of misfolded Hsp90 could also be linked 
to neurodegenerative diseases. Drawing upon the many parallels between AD and 
cancer, misfolded Hsp90 might be a cellular response to stress, which in turn facilitates 
Hsp90 for exosomal secretion. However, there are no reports of extracellular Hsp90 in 
neurodegenerative diseases, and rather than surviving like cancer cells in the harsh 
environmental stress associated within the microenvironment, neuronal cells die with 
increased kinase signaling and tau accumulation189-191. Neurodegenerative diseases, such 
as AD, could differentiate the impact that extracellular Hsp90 has on cell survival and 
migration, and whether misfolded protein is correlated to extracellular chaperone 
expression or simply a molecular cue of cellular stress.  
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The presence of Hsp90 on the surface of neuronal cells is not unprecedented. 
Over 20 years ago the Patsavoudi lab discovered Hsp90α in the membrane fraction of 
developing rat brains192. Using an antibody (4C5) specific for this protein, they followed 
up their study by demonstrating that Schwann cells were positive for surface Hsp90 
following mechanical injury193. Schwann cell motility was significantly decreased when 
treated with the 4C5 antibody194. This cumulative data points to a physiological role for 
extracellular Hsp90 in neural morphogenesis and neuronal repair by promoting cell 
motility.  
Embryonic morphogenesis shares more characteristics with cancer development 
than with neural degeneration. Thus it would not be alarming if Hsp90, in particular 
ectopic and misfolded Hsp90, were different between cancer and neurodegenerative 
diseases. Extracellular Hsp90 appears to play more of role that resembles epithelial to 
mesenchymal transformations (EMT), which is more of a tumor phenotype and will be 
discussed in the next chapter. Despite the incongruence of Hsp90 in cancer and AD, the 
young field of Hsp90 inhibition in neurodegenerative diseases is beginning to show 
some promise. Perhaps just as many doubted the relevance of Hsp90 inhibitors in 
cancer, so too will Hsp90 inhibitors blossom into a clinically significant therapeutics to 
treat complex neural diseases such as AD.  
 
 
 121 
7. Mechanisms of internalization and secretion 
7.1 Non-cancer mechanisms of receptor-mediated 
internalization of extracellular chaperones 
While the importance of extracellular Hsp90 in cancer progression and detection 
has been highlighted, there are several unknown aspects concerning the mechanisms by 
which ectopic Hsp90 is internalized. Many comparisons can be made between the 
internalization and processing of antigens and chaperones in the cross-presentation 
pathway in antigen presentation cells (APCs) and the chaperone/inhibitor 
internalization in cancer. 
Grp94 in particular has been studied for its participation in antigen presentation 
in several cancers, which activates the immune system to recognize and destroy tumor 
cells195,196. Chaperones, such as Grp94 and Hsp90α, are secreted from stressed cells and 
they enter professional APCs (e.g. dendritic cells and macrophages). Once internalized, 
the chaperones and their bound peptides undergo cross-presentation by forming 
complexes with the cell’s major histocompatibility complex (MHC) class I. These antigen 
complexes enable CD8+ cytotoxic T lymphocytes (CTL) recognition, and once activated, 
the CTL can search for the source of the antigen and destroy the cell197-199.  Hsp90α is 
specifically implicated as a contributor to the antigen cross-presentation pathway in 
dendritic cells as Imai et al showed in in vitro and in vivo knock out studies200.  
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Grp94 has been shown to be endocytosed by active receptor-mediated 
mechanisms as evidenced by colocalization studies with transferrin and electron 
micrograph images demonstrating the presence of the protein in endosomes. 
Additionally, some internalization was inhibited by DMA, which was attributed to fluid 
phase macropinocytosis but could also be explained by its inhibition on exosomal 
release201.   
Besides transferrin, there are other receptors that are more mechanistically linked 
to the internalization of extracellular chaperones. Stabilin-1 has been demonstrated to 
endocytose both Hsp90 and Hsp70 along with cargo, however, this internalization 
bypasses the steps of MHC receptor association202. Another potential receptor involved 
in endocytosis of Hsp90 is the scavenger receptor expressed by endothelial cells, SREC-
1. SREC-1 has demonstrated the ability to internalize Hsp90-OVA polypeptide 
complexes through a Cdc42-dependent manner203.  
LRP1 is also implicated in the internalization of chaperone/antigen complexes in 
APCs because of the established interaction with several chaperones and the 
upregulation of pro-inflammatory cytokines such as IL-1β, TNF-α and IL-6 upon 
receptor stimulation with extracellular chaperones204-206.  
7.1.1 LRP1 is a potential receptor for exHsp90 
LRP1 is a large endocytic receptor that belongs to the LDLR family. LRP1 binds 
and endocytoses over 30 distinct ligands including apolipoprotein, proteinases, 
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proteinase inhibitor complexes, extracellular matrix proteins, chaperone proteins and 
urokinase-type plasminogen activator207,208.  There is an on-going debate on the function 
of LRP1 in cancer cell migration and invasion , whether LRP1 facilitates or hinders the 
processes that lead to metastasis209-217. In comparing these reports, it appears the results 
are cell specific, even within disease models and whether or not the studies are 
conducted in vitro or in vivo. Understanding that cancer cells require extracellular 
chaperones for migration and invasion in addition to the presence of LRP1, one could 
distinguish the difference between these reported discrepancies by implicating 
extracellular Hsp90 as a prerequisite for LRP1 to facilitate cancer progression.  
In one study of interest, researchers found that Hsp90 secretion can result from 
TGFα stimulation through the exosome-secretion pathway. The secretion of Hsp90 
translates into a promotility signaling cascade via the LRP1 receptor98. The middle 
domain and charged linker region are primarily implicated in LRP1 binding and cell 
migration, which suggests an ATPase-independent function for Hsp9098. One 
consistency found in several papers is that hypoxic conditions upregulate LRP1 through 
Hif-1α. Cells that have low levels of LRP1 in vitro show increased levels in in vivo 
xenografts in SCID mice218. Additionally, cells that express low levels of LRP1 show 
increased protein levels upon treatments that induce Hif-1α levels218. 
Without knowing the precise mechanism of Hsp90 internalization, it appears to 
play a pivotal role in the cross-presentation of antigens in APCs resulting in an 
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antitumor response. Despite the tumor-alerting role of extracellular chaperones in 
adaptive immunity, ectopic Hsp90 significantly enables tumors to survive and progress 
towards malignancy. Because of this dichotomous relationship, off target effects on T 
cell activation are seen as a minor trade for the increasing benefits of Hsp90 inhibition 
that negatively affect cancer growth, motility, metabolism and survival.  
7.2 Non-cancer mechanisms of extracellular Hsp90 expression  
Cancer is a master of mimicry, often by ectopic gene expression of established 
developmental signaling pathways. Wound healing is another process that draws 
numerous parallels with cancer signaling and progression. Indeed, extracellular Hsp90 
plays a role in both processes, beneficially promoting cellular events in wound healing 
and on the other hand detrimentally facilitating events that lead to metastasis. Not 
surprisingly, LRP1 is also involved in both wound repair and cancer malignancy219,220. 
In addition to the similarities shared in the signaling axis of extracellular Hsp90 
and LRP1, many features of the wound healing environment are analogous to the tumor 
microenvironment such as disrupted vasculature with its accompanied hypoxia and 
angiogenesis, inflammation, matrix remodeling and cell motility and invasion221. A key 
difference is not in the expression pattern of genes and proteins that lead to the array of 
cellular processes but the duration of expression. In wound healing the signaling events 
are acutely regulated, whereas in cancer the same pathways are persistently turned on. 
As stated earlier, Hsp90 appears to play a central role in these processes. While 
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intracellular Hsp90 facilitates many signaling aspects, it is the extracellular expression 
that is truly unique. Understanding the Hsp90 secretion mechanisms should give insight 
into the important pathways that regulate wound healing and cancer progression. 
Furthermore, if the cessation of extracellular Hsp90 is mechanistically correlated to the 
acute regulation of wound healing processes then we might have increased 
comprehension on how to impede tumor cellular activities that depend on extracellular 
Hsp90. So how does ectopic Hsp90 occur? Despite the lack of an extracellular signal 
peptide, Hsp90 is secreted from its normal cytoplasmic residence to the extracellular 
milieu by exosomal secretion98,106,222,223.  Mechanisms regulating Hsp90 secretion have 
been reviewed and are linked to DNA damage, oxidative stress, chemotherapeutic 
agents , growth factors, heat stress and hypoxia65.  
Several studies have shown that posttranslational modifications are present on 
the extracellular Hsp9014. Some researchers suggest that the phosphorylation of T5 and 
T7 of Hsp90α is responsible for the translocation of Hsp90 to the cell membrane, and it 
has also been demonstrated that the secretion of Hsp90 was determined by the 
phosphorylation status at residue T90 and regulated by PKA and PP590,224. While these 
modifications might be detected at the picogram level by immunoblotting, they might 
not be the biologically important driver of extracellular expression. In our lab, we have 
searched by mass spectrometry for these posttranslational modifications and no 
consensus on a driving modification can be made by our analysis. Another group 
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published that extracellular Hsp90 is present as a C-terminal truncated form that fits 
another group’s model that only a segment of 115 amino acids in the middle domain is 
sufficient to stimulate cell migration in an in vitro assay98,225. While most of these studies 
underline the promotility function of Hsp90, the mechanism of secretion is poorly 
understood. Regardless of the uncertainty of the mechanism on how Hsp90 is excreted, 
there is a consensus that the secretion of Hsp90 is a prerequisite for pro-invasive 
functions and blocking the secreted Hsp90 results in significant inhibition of tumor 
migration and metastasis. 
In the context of our data, the misfolded Hsp90 found in cancer may be the 
source of extracellular Hsp90. Both the misfolded protein and extracellular expression 
are unique to breast cancer. The extracellular functions of Hsp90 appear to act 
independently of ATP hydrolysis, which fits the data that this population of Hsp90 
cannot be recovered on affinity chromatography resins. Misfolded Hsp90 might be more 
accessible to posttranslational modifications or display more exposed sequences that are 
preferentially loaded into exosomes. One way to test this hypothesis is to look for the 
presence of misfolded protein in exosomal extracts. The presence of misfolded Hsp90 in 
exosomes would suggest that they are targeted for exosomal secretion. This would 
support the model that the primary purpose of ectopic Hsp90 is to serve as a danger cue 
to the surrounding cells by activating promotility signaling pathways and activating 
cells in the adaptive immune system.  
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Even without a complete comprehension of Hsp90 secretion and internalization, 
extracellular Hsp90 can serve as a revolutionary cancer target for selective detection and 
treatment. The data we have shown using fluor-tethered Hsp90 inhibitors underscores 
the potential of such clinical applications.  
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Appendix A 
Synthesis Procedures for Affinity Probes as detailed and performed by Dr. Hughes. 
Reagents were obtained from commercial sources and used without further 
purification.  Proton NMR spectra were obtained on Varian 400 and 500 MHz 
spectrometers.  LC/MS were obtained on an Agilent ion-trap LC/MS system.  HRMS 
results were obtained on an Agilent 6224 LCMS-TOF and are reported as an average of 
four runs.   
HS-10 
N
N
O
N
H
O
NH2
OH
 
HS-10 was prepared as previously described40,47. 
HS-23 
N
N
O
N
H
H2N O
O
O
O
O
O NH2
 
HS-23 was prepared as previously described47. 
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2-((1-((3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)amino)-1-thioxo-
6,9,12,15,18-pentaoxa-2-azahenicosan-21-yl)amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-
tetrahydro-1H-indazol-1-yl)benzamide (HS-27).  Fluorescein 5(6)-isothiocyanate (35 mg, 
90 µmol) was dissolved in ethanol (10 mL) and treated with amine HS-23 (54.2 mg, 90 
µmol) followed by Hunig’s base (35 mg, 270 µmol) and stored in a drawer overnight.  
TLC (CH2Cl2/MeOH/AcOH : 4/1/0.1) showed formation of a new product.  The reaction 
mixture was concentrated to a glass and dissolved in DMSO/water (4/1, 2.5 mL).  About 
half of the product was purified in two injections by chromatography (5 to 100% MeOH, 
Agilent C-18 21.2 x 250 mm) to give the product (HS-27) (45 mg) as a yellow solid.  TLC 
(4/0.9/0.1 : CH2Cl2/MeOH/NH3) Rf = 0.3; 1H NMR (DMSO-d6) δ 10.2 (br s, 2H), 8.40 (br t, 
1H), 8.34 (br s, 1H), 8.23 (s, 1H), 7.92 (b s, 1H), 7.73 (d, J = 8.1 Hz, 2H), 7.26 (br s, 1H), 7.15 
(d, J = 8.1 Hz, 1H), 6.76 (s, 1H), 6.67 (s, 1H), 6.65 (br s, 2H), 6.59 (d, J = 8.5 Hz, 2H), 6.54 (d, 
J = 8.5 Hz, 2H), 3.47 (m, 20H), 3.19 (m, 2H), 2.91 (s, 2H), 2.38 (s, 3H), 2.31 (s, 2H), 1.79 (m, 
4H), 1.00 (s, 6H); 13C NMR (DMSO-d6) δ 13.57, 28.19, 29.01, 29.24, 35.79, 36.96, 40.13, 
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40.31, 41.86, 52.24, 68.38, 68.62, 70.01, 70.06, 70.17, 70.22, 70.26, 102.69, 105.56, 108.65, 
110.20, 113.05, 113.37, 116.81, 124.47, 127.01, 129.47, 130.71, 141.83, 142.10, 147.53, 148.67, 
149.92, 151.00, 152.34, 159.97, 168.97, 171.31, 180.85, 193.27; HRMS (ESI) [M+H]+ calcd for 
C52H61N6O12S, 993.4063; found 993.4065. 
HS-32 
 
N
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O
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O
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2-((19-(ferrocenemethylamino)-4,7,10,13,16-pentaoxanonadecyl)amino)-4-(3,6,6-
trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide (1) and 2-((19,19-
di(ferrocenemethylamino)-4,7,10,13,16-pentaoxanonadecyl)amino)-4-(3,6,6-trimethyl-4-
oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide (HS-32). Amine HS-23 (673 mg, 1.11 
mmol) and ferrocene carboxaldehyde (239 mg, 1.11 mmol) were dissolved in 
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dichloroethane (5 mL) and treated with sodium triacetoxy-borohydride (283.5 mg, 1.34 
mmol) followed by acetic acid (77 µL).  The reaction mixture was stirred over the 
weekend.  The mixture was adsorbed onto silica (3 g), added to a dry column (1.5 x 12 
cm silica gel) and eluted with 100%, 19/1/0.1, then 9/1/0.1 : CH2Cl2/MeOH/NH4OH (300 
mL ea.) to give the less polar product  (~180 mg) and the more polar product (~650 mg), 
both as yellow glasses.  The products were separately dissolved in DMSO and 
chromatographed by HPLC (Agilent Prep C-18, 2.5 x 25 cm, 5 to 100 % MeOH w/2% 
formic acid) to give 1 (490 mg, 54%)  and HS-32 (200 mg, 17%)  as viscous yellow glasses.  
1. TLC (9/0.9/0.1 CH2Cl2/MeOH/NH3) Rf = 0.23; 1H NMR (CDCl3) δ 8.52 (s, 1H), 7.98 (br 
s, 1H), 7.51 (d, J= 8.1 Hz, 1H), 6.78 (d, J = 1.6 Hz, 1H), 6.59 (dd, J = 1.6, 8.1 Hz, 1H), 6.44 
(br s, 1H), 4.3 (br s, 2H), 4.16 (br s, 2H), 4.11 (s, 5H), 3.91 (br s, 2H), 3.57 (br m, 20H), 3.28 
(br s, 2H), 2.97 (br t, 2H), 2.79 (s, 2H), 5.52 (s, 3H), 2.37 (s, 2H), 1.91 (br m, 4H), 1.08 (s, 
6H); 13C NMR (CDCl¬3) δ 193.60, 171.80, 167.86 (formate), 151.11, 149.85, 149.21, 142.54, 
130.06, 117.15, 112.81, 108.95, 106.17, 77.43, 70.59, 70.57, 70.53, 70.51, 70.46, 70.34, 70.20, 
70.09, 69.42, 68.99, 68.93, 68.88, 52.44, 46.72, 44.54, 40.20, 37.56, 35.88, 29.16, 28.46, 25.76, 
13.50; MS (ESI): m/z 802.4 [M+H]+; HRMS (ESI) [M+H]+ calcd for C42H60FeN5O7, 
802.3831; found 802.3846. 
HS-32 TLC (9/0.9/0.1 CH2Cl2/MeOH/NH3) Rf = 0.40; 1H NMR (CDCl¬3) δ 8.51 (s, 1H), 
8.06 (br s, 1H), 7.51 (d, J = 8.4 Hz, 1H), 6.77 (d, J = 1.9 Hz, 1H), 6.59 (dd, J = 1.9, 8.4 Hz, 
1H), 6.04 (v br s, 1H), 4.32 (br s, 4H), 4.21 (br s, 4H), 4.11 (s, 10 H), 3.88 (br s, 4 H), 3.54-
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3.63 (m, 14H), 3.52 (m, 2H), 3.45 (m, 2H), 3.35 (t, J = 5.5 Hz, 2H), 3.28 (m, 2H), 2.79 (s, 2H), 
2.70 (m, 2H), 2.51 (s, 3H), 2.37 (s, 2H), 1.93 (p, J = 6.1 Hz), 1.86 (m, 2H), 1.07 (s, 6H);  13C 
NMR (CDCl¬3) δ 193.56, 171.54, 167.71 (formate), 151.16, 149.84, 149.17, 142.54, 129.92, 
117.15, 112.68, 108.89, 106.17, 75.49, 71.23, 70.60, 70.57, 70.56, 70.46, 70.36, 70.21, 69.57, 
69.13, 69.06, 68.99, 68.92, 68.30, 52.44, 51.78, 47.22, 40.19, 37.56, 35.87, 29.20, 28.46, 24.82, 
13.50; HRMS (ESI) [M+H]+ calcd for C53H70Fe2N5O7, 1000.3969; found 1000.3978. 
HS-42 
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N
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N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-
(methylsulfonyl)ethyl)amino)methyl)¬furan-2-yl)quinazolin-4-amine (2). Four lapatinib 
pills (assume 250 mg drug each) were partitioned between saturate sodium bicarbonate 
solution (100 mL) and ethyl acetate (100 mL) and vigorously stirred for 16 hours.  The 
mixture was filtered to remove the solids, the layers separated and the aqueous layer 
washed with more ethyl acetate (50 mL).  The combined organic layers were washed 
with brine (50 mL), dried (NaSO4), filtered and concentrated to give the product (1.09 g) 
as a yellowish solid.  The solid was dissolved in hot ethyl acetate and diluted with 
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hexanes, which quickly gave crystals.  The mixture was stirred rapidly until cool and the 
solid was filtered off to give purified Lapatinib (2) (968 mg) as an off white solid. 
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6-(5-(((3-bromopropyl)(2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)-N-(3-chloro-4-
((3-fluorobenzyl)oxy)phenyl)quinazolin-4-amine (3). Lapatinib (2) (500 mg, 860 µmol) 
was dissolved in DMF (2 mL) and treated with 1,3-dibromopropane (2.6 g, 12.9 mmol) 
and Hunig’s base (450 µL) and stirred at RT for 4 days.  The mixture was partitioned 
between water (30 mL) and ethyl acetate (60 mL).  The resulting emulsion was filtered to 
give separation.  The aqueous layer was re-extracted with ethyl acetate (30 mL) and the 
combined organic layers washed with brine (30 mL).  The organic layer was treated with 
silica gel (2.5 g) and concentrated to a powder.  The powder was added to a column and 
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chromatographed (silica gel 18 x 2.5 cm, EtOAc) to give product which was 
recrystallized in hexane/ethyl acetate to give 11 (174 mg, 29%) as a yellow solid. 1H 
NMR (DMSO-d6) δ 9.88 (s, 1H), 8.74 (s, 1H), 8.55 (s,1H), 8.13 (d, J = 8.8 Hz, 1H), 8.02 (d, J 
= 2.4 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.74 (dd, J = 2.4, 8.8 Hz, 1H), 7.47 (q, J = 8 Hz, 1H), 
7.33 (d, J = 8 Hz, 1H), 7.28 (d, J = 8 Hz), 7.17 (dt, J = 2.8, 1H), 7.08 (d, J = 3.3 Hz, 1H), 6.57 
(d, J = 3.3 Hz, 1H), 5.25 (s, 2H), 3.79 (s, 2H), 3.57 (t, J = 6.9 Hz, 2H), 3.37 (t, J = 6.9 Hz, 2H), 
3.05 (s, 3H), 2.93 (t, J = 6.7 Hz, 2H), 2.63 (t, J = 6.9 Hz, 2H), 2.00 (p, J = 6.8 Hz, 2H);  13C 
NMR (DMSO-d6) δ 163.80, 160.58, 157.57, 152.48, 151.96, 149.81, 139.68, 139.57, 130.60, 
130.49, 128.29, 124.33, 123.34, 123.29, 122.52, 121.04, 115.30, 114.82, 114.54, 114.30, 114.16, 
113.87, 111.64, 107.84, 69.39, 51.13, 51.09, 49.02, 46.79, 41.49, 33.08, 29.81; HRMS (ESI) 
[M+H]+ calcd for C32H32BrClFN4O4S, 701.1007; found 701.1003. 
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N1-(3-(((5-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-
yl)methyl)(2-(methylsulfonyl)ethyl)amino)propyl)-4,7,10,13,16-pentaoxanonadecane-
1,19-diamine (4).  Bromide (3) (100 mg, 142 µmol) was treated with 1,19-diamino-
4,7,10,13,16-pentaoxanonadecane (439 mg, 1.42 mmol) followed by DMSO (400 µL) with 
vigorous stirring.  After 40 m, the entire reaction mixture was injected on the Prep HPLC 
(5 to 100% methanol, 20 mL/m, Agilent C-18, 21.1 x 25 cm) to give amine (4) (48 mg, 
36%) as a yellow glass. 1H NMR (DMSO-d6) δ 8.82 (s, 1H), 8.53 (s, 1H), 8.31 (s, formate), 
8.12 (dd, J = 1.5, 8.8 Hz, 1H), 8.02 (d, J = 2.5, 1H), 7.78 (d, J = 8.8 Hz, 1H), 7.74 (dd, J = 2.5, 
8.8 Hz, 1H), 7.45 (dt, J = 6.3, 8.0 , 1H), 7.32 (d, J = 6.9 Hz, 1H), 7.30 (dm, J = 8.8 Hz, 1H), 
7.24 (d, J = 8 Hz, 1H), 7.15 (tm, J = 8.8 Hz, 1H), 7.07 (d, J = 3.3 Hz, 1H), 6.56 (d, J = 3.3 Hz, 
1H), 5.24 (s, 2H), 3.78 (s, 2H), 3.39-3.52 (m, 18H), 3.36 (t, J = 6.2 Hz, 2H), 3.02 (s, 3H), 2.87-
2.98 (m, 6H), 2.83 (t, J = 7.1 Hz, 2H), 2.57 (bt, J = 6.2 Hz, 2H), 1.86 (m, 2H), 1.78 (m, 4H); 
13C NMR (DMSO-d6) δ 164.90 (formate), 163.90, 160.67, 157.73, 152.22, 152.18, 149.82, 
148.94, 139.78, 139.68, 133.26, 130.68, 130.57, 128.29, 124.47, 123.37, 123.33, 122.66, 121.11, 
115.51, 114.29, 114.20, 113.91, 111.95, 107.87, 69.79, 69.66, 69.49, 67.49, 67.43, 50.89, 50.24, 
48.48, 46.57, 45.35, 44.64, 41.47, 39.52, 36.83, 27.25, 25.95, 23.32; HRMS (ESI) [M+H]+ calcd 
for C46H63ClFN6O9S, 929.4044; found 929.4045. 
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2-((1-((3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)amino)-1-thioxo-
6,9,12,15,18-pentaoxa-2-azahenicosan-21-yl)amino)-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-
tetrahydro-1H-indazol-1-yl)benzamide (HS-42). Amine (4) (24 mg, 34 µmol) was 
dissolved in ethanol (1 mL) and treated with fluorescein isothiocyanate (13.3 mg, 34.2 
m ol) follow ed  by Hu n ig’s base (9 mg) and  stirred  for 3 d ays.  The m ixtu re w as d ilu ted  
with DMSO and ethanol, then concentrated to an oil and injected on the prep HPLC (5 to 
100% methanol, 20 mL/m, Agilent C-18, 21.1 x 25 cm).  The product was collected and 
concentrated to give the fluorescein derivative (HS-42) (14 mg, 31%) as a yellow glass. 
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(ESI): base peak at m/z 1317.0 [M]-. 
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Synthesis of HS-10 has been previously described47. 
2-((19-((2-carbamoyl-5-(3,5,5-trimethyl-7-oxo-4,5,6,7-tetrahydro-1H-indazol-1-
yl)phenyl)amino)-4,7,10,13,16-pentaoxanonadecyl)amino)-4-(3,6,6-trimethyl-4-oxo-
4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide HS-66. A mixture of 2-fluoro-4-(3,6,6-
trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile 5 (500 mg, 1.6 mmol), 
1,19-diamino-4,7,10,13,16-pentaoxanonadecane (260 mg, 840 µmol) and Hunig’s base 
(520 mg, 4.0 mmol) in DMSO (1 ml) in a 60 mL EPA vial was stirred at 40°C for 2 days.  
The mixture was then diluted with ethanol (10 mL), heated to 90°C and treated with 10 
drops of 50% sodium hydroxide followed by very slowly addition of 10 drops of 30% 
hydrogen peroxide.  TLC (4/0.9/0.1 : CH2Cl2/MeOH/NH3) showed complete conversion 
to new products.  The mixture was adsorbed onto silica gel (3 g), concentrated to a solid, 
added to a column and chromatographed (3.5 x 20 cm, CH2Cl2 (200 mL), CH2Cl2/MeOH 
19/1 (300 mL), 9/1 (300 mL) and 4/1 (200 mL)) to give product as a glass.  The glass was 
 139 
recrystallized in ethyl acetate/hexanes to give the product HS-66 (360 mg, 47 %) as a 
white powder.  TLC (4/0.9/0.1 : CH2Cl2/MeOH/NH3) Rf = 0.33; 1H NMR (DMSO-d6) δ 
8.42 (t, J = 5.3 Hz, 2H), 7.92 (br s, 2H), 7.73 (d, J = 8.5 Hz, 2H), 7.25 (br s, 2H), 6.7602 (d, J = 
2.0 Hz, 2H), 6.66 (dd, J = 2.0, 8.5 Hz, 2H), 3.41-3.51 (m, 20H), 3.19 (dd, J = 6.5, 12.2 Hz, 
4H), 2.9046 (s, 4H), 2.38 (s, 6H), 2.30 (s, 4H), 1.79 (p, J = 6.4 Hz, 4H), 0.99 (s, 12H); 13C 
NMR (DMSO-d6) δ 192.77, 170.84, 150.54, 149.44, 148.19, 141.64, 130.24, 116.35, 112.89, 
108.17, 105.09, 69.77, 69.73, 69.69, 69.59, 67.90, 51.77, 36.49, 35.32, 28.78, 27.72, 13.09 ; 
HRMS (ESI) [M+H]+ calcd for C48H67N8O9, 899.5026; found 899.5029. 
HS-69 
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VivoTag 645 compound (HS-69). Amine HS-23 (4.5 mg, 7.45 µmol) was dissolved in 
DMSO (200 µL) and added to VivoTag 645 (Perkin Elmer, 2.5 mg, 1.8 µmol) in its 
original container and placed back into the freezer overnight.  The sample was purified 
in 3 portions by reverse-phase chromatography and concentrated to give VivoTag 645 
compound (HS-69) (~3 mg) as a blue solid.  MS (ESI): m/z 1577.5 [M-].  
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LC/MS 
 
HPLC (C-18, 0 to 100% acetonitrile w/ 1% TFA over 30 min, hold at 100% 10 min.).  
Fluorescent traces were obtained by collection of 15 sec fractions into a microtiter plate 
followed by buffering the wells to pH 7.4 and counting in a plate reader. 
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UV trace (254 nm) 
 
Fluorescence trace 
 
HS-70 
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VivoTag 800 compound (HS-70). Amine HS-23 (4.3 mg, 7.2 µmol) was dissolved in 
DMSO (100 µL) and treated with Hunig’s base (10 µL) and added to VivoTag 800 (Perkin 
Elmer, 5 mg, 3.42 µmol) in its original container.  The starting material vial was washed 
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twice with DMSO (100 µL), which was added to the reaction mixture.  The mixture was 
left in an aluminum bag at RT for 30 minutes, then placed back into the freezer for the 3 
days.  The sample was purified in 3 portions by reverse-phase chromatography and 
concentrated to give VivoTag 800 compound (HS-70) (~9 mg) as a blue solid.  MS (ESI): 
m/z 823.7  [M-2]2-. 
LC/MS 
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UV trace  
 
Fluorescence trace 
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A solution of  NHS-dPEG® 4-biotin 6 (Quanta Biodesign Pt # 10200, 13.3 mg, 22.4 µmol) 
in DMF (200 µL) was added to HS-23 (13.6 mg, 22.5 µmol) and Hunig’s base (15 mg, 110 
µmol).  TLC (2/0.9/0.1 CH2Cl2/MeOH/NH3) showed pretty clean formation of a new 
product so the entire reaction mixture was injected on the Prep HPLC (5 to 100% 
methanol, 20 mL/m, Agilent C-18, 21.1 x 25 cm) and the product collected and 
concentrated to give HS-96 (16 mg. 67%) as a clear glass. MS (ESI): m/z 1077.7  [M+H]+. 
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HS-105 
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1-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-3-(3-
ethoxypropyl)thiourea HS-105.  FITC (75 mg, 193 µmol) was slurried in methylene 
chloride (4 mL) and treated with 3-ethoxypropylamine (80 mg, 770 µmol) with rapid 
stirring for 30 m.  The mixture was concentrated then chromatographed (silica gel 2.5 x 
20 cm, CH2Cl2 (100mL), then CH2Cl2/MeOH/AcOH : 9/1/0.05 (400 mL)) to give an orange 
glass (82 mg).  The glass was dissolved in some ethanol and diluted with water to effect 
solidification.  Some of the ethanol was removed and the solid filtered off and air dried 
to give the product HS-105 (62 mg, 65%) as an orange powder.  1H NMR (CDCl¬3) δ 
10.12 (s, 2H), 9.89 (br s, 1H), 8.20 (s, 1H), 8.06 (br s, 1H), 7.73 (d, J = 8 Hz, 1H), 7.18 (d, J = 
8 Hz, 1H), 6.68 (d, J = 2.3 Hz, 2H), 6.61 (d, J = 8.7 Hz, 2H), 6.56 (dd, J = 2.3, 8.7 Hz, 2H), 
3.56 (br m, 2H), 3.44 (d, J = 7 Hz, 2H), 3.43 (q, J = 7 Hz, 2H), 1.81 (p, J = 7 Hz, 2H), 1.11 (t, J 
= 7 Hz, 2H). 13C NMR (CDCl¬3) δ 180.44, 168.45, 159.44, 159.19, 151.82, 128.96, 124.05, 
120.64, 119.61, 119.38, 112.51, 109.74, 102.24, 102.22, 83.05, 67.65, 65.4, 41.53, 28.69, 15.18; 
HRMS (ESI) [M+H]+ calcd for C26H25N2O6S, 493.1428; found 493.1438. 
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HS-111 
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N-(19-((2-carbamoyl-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-
yl)phenyl)amino)-4,7,10,13,16-pentaoxanonadecyl)-3-iodobenzamide HS-111. The free 
amine, 2-((19-amino-4,7,10,13,16-pentaoxanonadecyl)amino)-4-(3,6,6-trimethyl-4-oxo-
4,5,6,7-tetrahydro-1H-indazol-1-yl)benzamide HS-23 (55 mg, 91 µmol), 3-iodobenzoic 
acid (23 mg, 92 µmol), EDC (27 mg, 137 µmol), HOBT (12 mg, 91 µmol) and Hunig’s base 
(20 µL) were dissolved in DMSO (400 µL) and stirred at RT for one hour.  The reaction 
mixture injected onto the HPLC (30 to 100% methanol, 20 mL/m, Agilent C-18, 21.1 x 25 
cm) to give purified product HS-111 (38 mg, 50%) as a clear glass. TLC (9/1 : 
CH2Cl2/MeOH) Rf = 0.51; 1H NMR (CDCl3) δ 8.10 (t, J = 1.6 Hz, 1H), 7.96 (br t, J = 4.7 Hz, 
1H), 7.74 (d m, J = 7.6 Hz, 1H), 7.73 )d m, J = 7.6 Hz, 1H), 7.47 (d, J = 8.3 Hz, 1H), 7.32 (br 
t, J = 4.7 Hz, 1H), 7.11 (t, J = 7.6 Hz, 1H), 6.76 (d, J = 2.0 Hz, 1H), 6.57 (dd, J = 2.0, 8.3 Hz, 
1H), 6.01 (br s, 1H), 3.48-3.63 (m, 22H), 3.26 (br q, 2H), 2.78 (s, 2H), 2.50 (s, 3H), 2.37 (s, 
2H), 1.9 (p, J = 6 Hz, 2H), 1.84 (p, J = 6 Hz, 2H), 1.06 (s, 6H); 13C NMR (CDCl3) δ 193.66, 
171.49, 165.87, 151.18, 150.07, 149.29, 142.77, 140.17, 137.07, 136.27, 130.32, 129.76, 126.46, 
117.32, 112.83, 109.09, 106.44, 94.31, 77.65, 77.23, 76.81, 70.79, 70.69, 70.68, 70.67, 70.61, 
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70.60, 70.49, 70.49, 70.40, 69.12, 52.57, 40.45, 39.26, 37.72, 36.01, 29.26, 28.85, 28.59, 13.61; 
HRMS (ESI) [M+H]+ calcd for C38H53IN5O8, 834.2933; found 834.3195. 
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This procedure was adapted from published procedures226,227. 
N-(19-((2-carbamoyl-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-
yl)phenyl)amino)-4,7,10,13,16-pentaoxanonadecyl)-3-(trimethylstannyl)benzamide (7).  
N-(19-((2-carbamoyl-5-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-
yl)phenyl)amino)-4,7,10,13,16-pentaoxanonadecyl)-3-iodobenzamide (HS-111) (92.7 mg, 
111 µmol), hexamethylditin (40 mg, 122 µmol) and tetrakis triphenylphosphine 
palladium(0) (2.6 mg 2.22 µmol) were slurried in dioxane (2 mL), purged with nitrogen 
and heated to 100 °C for 1 h, then 80 °C for 16h.  The reaction mixture was concentrated 
then added to a column and chromatographed (silica gel, 2.5 x 25, CH2Cl2 (100 mL), 
CH2Cl2/MeOH : 19/1 (250 mL), CH2Cl2/MeOH : 9/1 (250 mL)) to give the product (7) (91.8 
mg, 95%) as a slightly yellowish oil. TLC (9/1 CH2Cl2/MeOH) Rf = 0.46; 1H NMR 
(CDCl3) δ 7.97 (bt, 1H), 7.92 (sm, 1H), 7.64 (dm, J = 7.2 Hz, 1H), 7.55 (dm, J = 7.2 Hz, 1H), 
7.47 (d, J = 8.3 Hz, 1H), 7.32 (tm, J = 7.2 Hz, 1H), 7.12 (brt, 1H), 6.76 (d, J = 2 Hz, 1H), 6.57 
(dd, J = 2,8.3 Hz, 1H), 5.94 (vbrs, 1H), 3.49-3.62 (m, 22 H), 3.26 (q, J = 6.5 Hz, 2H), 2.78 (s, 
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2H), 2.50 (s, 3H), 2.36 (s, 2H), 1.91 (p, J = 6.2 Hz, 2H), 1.85 (p, J = 6.2 Hz, 2H), 1.07 (s, 6H), 
0.27 (s, 9H). 13C NMR (CDCl3) δ 193.69, 171.45, 168.10, 151.19, 150.08, 149.29, 143.13, 
142.78, 138.84, 134.70, 129.75, 128.60, 127.98, 126.62, 117.33, 112.84, 109.09, 106.45, 70.68 
3C), 70.63 (2C), 70.59, 70.51, 70.47, 70.39, 69.13, 52.57, 40.45, 38.79, 37.72, 36.02, 29.25, 
29.11, 28.59, 13.61, -9.27;  (ESI): base peak at m/z 858.4 [M]+.  HRMS (ESI) [M+H]+ calcd 
for C41H61N5O8116Sn, 868.3626; found 868.3623. 
125I-HS-111 
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Sodium [125I]iodide (2200 Ci/mmol) as a solution in 0.1N NaOH was procured from 
Perkin Elmer Life and Analytical Sciences (Boston, MA).  High-pressure liquid 
chromatography (HPLC) was performed using a Beckman Gold HPLC system equipped 
with a Model 126 programmable solvent module, a Model 166 NM variable wavelength 
detector, a Model 170 radioisotope detector and a Beckman System Gold remote 
interface module SS420X; data was acquired using the 32 Karat® software.  Reversed-
phase HPLC was performed using a Waters 4.6 × 250-mm XTerra RP18 (5 :m) column.  It 
was eluted at a flow rate of 1 ml/min with a gradient consisting of 0.1% TFA in water 
(solvent A) and 0.1% TFA in acetonitrile (solvent B).  The proportion of solvent B was 
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linearly increased from 30% to 100% in 30 min and held at 100% for the next 5 min 
before restoring to original conditions. 
Compound 7 was dissolved in methanol (2.5 mg/ml) and a 10 µl aliquot of this 
was transferred to a small conical glass vial, and methanol was evaporated with a gentle 
stream of argon.  A solution of [125I]iodide in 0.1N NaOH (2 µl, about 500 µCi) was added 
to 7 (25 µg; 28.7 nmol) followed by a 5 µl of a solution of H2O2 (30% w/v) in acetic acid 
(1:3 v/v).  The vial with the contents was briefly sonicated (~20 sec) and the entire 
reaction mixture was injected onto a reversed-phase HPLC column eluted with the 
gradient conditions described above.  Under these conditions, the product (125I-HS-111) 
eluted with a tR of 15.3 min.  HPLC fractions containing [125I]HS-111 were pooled and 
most acetonitrile from them was evaporated with a gentle stream of argon and diluted 
with the addition of 10 ml of water.  This was passed through a C18 Seppak cartridge 
(Waters), which was pre-activated by eluting with 2 ml each of methanol and water.  
The cartridge was eluted with 2 × 5 ml water followed by 0.25 ml portions of methanol.  
Methanol fractions containing most of the radioactivity (typically 3-5) were pooled and 
methanol evaporated with argon.  The residual radioactivity was reconstituted in PBS. 
  Compound 7 was radioiodinated to obtain [125I]-HS-111 in an average 
radiochemical yield of 64.5 ± 5.6% (n = 4).  The product co-eluted with an authentic 
standard of HS-111 (see Figure 1. for HPLC) and had a radiochemical purity of greater 
than 98%.  No co-eluting peaks were seen in the HPLC profile of the reaction mixture 
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and thus the specific activity of the product is assumed to be that of starting radioiodide 
(2200 Ci/mmol).  
 
Quality control HPLC of [125I]HS-111: Final formulated [125I]HS-111 was co-injected onto 
the HPLC with an authentic standard of HS-111.  Upper-UV; Lower-Gamma 
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